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Abstract 
Human African trypanosomiasis (HAT) also known as sleeping sickness is caused by 
a subspecies of Trypanosoma brucei. These parasites are transmitted by tsetse flies 
and endanger over 60 million people in Sub-Saharan Africa. Untreated, sleeping 
sickness is fatal, causing at least 48.000 deaths per year. Its treatment remains 
complicated since the currently available drugs show high toxicity and are too 
expensive to be ubiquitously distributed in the affected third world economies. 
Additionally, emerging drug resistance towards the most clinically relevant anti HAT 
drugs, drastically limits treatment options and makes it imperative to conduct 
research to find safer and more efficient drugs to treat this terrible disease. 
This thesis describes the hit identification and hit validation for two validated 
targets for HAT: Tb6PGDH and TbUGP. For hit identification different techniques like 
in silico virtual screening, NMR lead-like fragment screening and HTS were used. For 
TbUGP a very first drug-like, competitive inhibitor with a pIC50 of 3.53±0.04 and a 
Hill slope of 1.1±0.1 was discovered. Additionally this thesis describes the 
determination and validation of the in silico proposed binding mode using mutation 
studies and crystallisation techniques  
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1 Introduction  
1.1 Drug discovery and drug design 
1.1.1 Drug discovery process 
In 7000 years of development of mankind, drug discovery has always played a 
crucial role (Lindesmith 1968). The more advanced the medicinal knowledge of a 
community was, the healthier and therefore longer-living and historically influential 
people were. Although hundreds of years ago many drugs were known, which were 
isolated from plants, animals and minerals, the knowledge and discovery of new 
drugs developed very slowly. With the beginning of the modern age, drugs from all 
over the world became available for trade with the consequence that drug 
discovery gathered speed. At the end of the 19th century organic-synthetically drugs 
had a major success. Drugs like sulfonamide (Prodrug Prontosil discovered 1932 by 
Gerhard Domagk) (Bickel 1988; Schirren 1988; van Miert 1994) or aspirin (isolated 
in 1897 by Felix Hoffmann)(Sneader 2000; Cheng 2007; Folts 2007; Schror 2009; 
Wick 2012) are still used ubiquitous. Nowadays, the drug discovery process is an 
established multibillion dollar project involving thousands of people worldwide. 
Modern drug discovery must meet many challenges like research and development 
speed, cost and quality, leadership and management, selecting the right 
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pharmacologic target and the right chemical lead (Elebring, et al., 2012). The 
current strategy starts with the search for a suitable target (Figure1.1).  
Figure1.1 The drug discovery pipeline 
 
This must have a therapeutic value and preferably be suitable to 
be manipulated with a small molecule to the desired function 
(Knowles and Gromo 2003). This is a crucial step, because 
concentrating on the wrong target is very time and cost intensive. For the selected 
target an assay must be developed which delivers robust and reproducible results. 
This assay may then be used in the hit discovery step. There are two possible ways 
to find hits: in silico screening and experimental screening. The in silico screening 
method will be described in detail later (1.1.3).  
Nuclear magnetic resonance (NMR) and surface plasmon resonance (SPR) are 
suitable for the hit validation step. Hereby, all hits must be retested to filter out 
false positives and confirm the other hits. False positive compounds mostly absorb 
at the wavelength where the assay is carried out, are fluorescent, interfere with the 
assay setup or are chemically impure and reactive. For this reasons the compounds 
are tested for purity using LCMS or NMR and are either repurchased or 
resynthesized for the retest. Usually a dose response curve will be measured in a 
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biochemical or cell assay to identify the binding mode of the compound 
(aggregator, allosteric inhibitor, etc.) and to rank the hits by their potency (IC50, 
EC50) (Alphey, et al., 2012). In the next step, the initial hits need to be improved to 
leads. Therefore, promising compounds are chemically modified and further tested. 
Here, not only the potency of the compound can be improved but also other 
important properties like lipophilicity, solubility, size, ligand efficiency and 
selectivity. All these modifications help to establish the structure activity 
relationship (SAR) of the preferred compound series. Subsequently, the candidate 
reaches the lead optimisation step, where it is further improved to meet the 
required pharmacokinetic and pharmacodynamics profile. In the preclinical studies 
the compounds are tested in vivo and in vitro for toxicity. Only if the chemical 
passes this tests, it will be used for humans in the clinical studies Ⅰ,Ⅱ and Ⅲ. In 
the very last step, all the studies must be provided to the relevant agency in order 
to get approval as a new drug, e.g. the Medicines and Healthcare products 
Regulatory Agency (MHRA) for a UK licence or the European Medicines Agency 
(EMA) for a Europe wide licence.  
1.1.2 Experimental screening 
In the experimental screening methods like high throughput screening (HTS), 
nuclear magnetic resonance (NMR), mass spectrometry (MS) or surface plasmon 
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resonance (SPR) are used to screen compound libraries for activity against the 
target.  
HTS plays a dominant role in modern drug discovery. The aim is to find active 
compounds (hits) by screening a large database of chemically diverse compounds 
against proteins, cells or other targets. This is possible, because HTS consists of 
multiple automated steps like liquid dispensing, compound transfer and signal 
capturing. This automation leads to low systematic failures during the screen and 
can generate highly reproducible and reliable data (Shun, et al., 2011). 
Unfortunately, HTS often produces also many false positive hits that slow down the 
process of drug finding (Crisman, et al., 2007; Posner, et al., 2009; Sink, et al., 2010; 
Bocker, et al., 2011; Liu, et al., 2012; Prummer 2012). Screening by NMR has been 
established as an alternative method (Bhunia, et al., 2012; Jordan, et al., 2012; 
Mizukoshi, et al., 2012; Stark and Powers 2012; Wirmer-Bartoschek and Bartoschek 
2012). Compared to HTS, it provides a cheap method to detect even weak protein-
ligand interactions, dissociation constant, identify a ligand binding site and generate 
a complex structure (Stark and Powers 2012).  
Since Lipinski et al., published the rule of 5 where he discovered, that orally 
available drugs do not violate more than the following criteria (Lipinski, et al., 1997; 
2001): 
• Molecular weight (MW) < 500 Daltons 
• Logarithmic octanol/water partition coefficient (logP) < 5 
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• Hydrogen-bond donors ≤ 5 
• Hydrogen-bond acceptors ≤ 10 
the compound databases could be easily filtered applying these rules (Matter, et al., 
2001). Shortly after Lipinski, Hann et al., discovered, that drug-like molecules were 
still too complex (too high MW, too many heavy atoms, etc.) to be used as a good 
starting point for drug discovery (Hann, et al., 2001) and suggested to use lead-like 
compounds instead. These lead-like compounds are less complex (less MW, less 
number of rings and rotatable bonds) and less hydrophobic (lower CLogP)(Oprea, et 
al., 2001). The advantage in using lead-like compounds as a starting point for drug 
discovery is, that these small, active molecules can gain in MW and CLogP while 
being optimised to become a drug-like candidate. Recently, the screening of 
fragment-like libraries was established (Badger 2012; Bower and Pannifer 2012; 
Duong-Thi, et al., 2012; Kumar, et al., 2012). Keeping this in mind, the NMR screen 
is sensitive enough to detect hits from small, fragment-like libraries. With the low 
MW of the fragments, the chemical space can be exploited much more effective. 
These fragment-like compounds are smaller (usually < 18 heavy atoms) and the hits 
therefore usually less potent. Traditional screening methods such as biochemical 
assays are often not effective enough to detect such weak binding. To detect 
weakly bound fragment-like compounds, biophysical screens like X-ray 
crystallography or NMR are used. The big advantage of X-ray crystallography is that 
it additionally gives the binding mode of the fragment. 
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1.1.3 In silico (virtual) screening 
Modern drug discovery would not be possible without using computational 
methods. These can be applied for hit-discovery using virtual screening of small 
molecule libraries, hit to lead optimisation and also to improve the psychochemical 
properties in the lead optimisation (Bernardo and Tong 2012; Cheng, et al., 2012; 
Ma, et al., 2012). There are several advantages of in silico screening compared to 
experimental screening methods. It is both, much cheaper and much faster 
compared to any experimental screening approach. Using computational power, 
the chemical space can be exploited more effectively by screening a large number 
of molecules. Even for a small compound with 12 heavy atoms, the number of 
potential drug-like molecules (not including 3- and 4-membered ring structures) has 
been estimated to be 107 (Fink, et al., 2005). This number is raising to 1060 
considering a compound with 30 heavy atoms (Bohacek, et al., 1996). Considering 
this large number, the only way to manage, screen and evaluate such datasets is by 
using in silico methods. The two major approaches of in silico drug screening are 
structure-based and ligand-based screening (Figure 1.2). Ligand-based screening is 
usually used if a set of structurally diverse ligands is available. The assumption is, 
that compounds found with a similarity search, will have a similar activity as the 
lead compound (Sheridan and Kearsley 2002; Bender, et al., 2009; Vilar, et al., 
2012). The method used in this thesis was a structure-based virtual screening 
(SBVS). This method is applied when a 3D structure of the biological target or a 
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homology model is available. When a binding site/pocket of the target is known, 
libraries of small molecules can be screened and the compounds will be predicted 
to bind into this site/pocket (Hurko 2012) using molecular docking programs like 
Gold (Jones, et al., 1997), DOCK (Lorber and Shoichet 1998) , Glide (Friesner, et al., 
2004; Halgren, et al., 2004), FlexX (Kramer, et al., 1999), Fred (McGann, et al., 2003) 
and LigandFit (Venkatachalam, et al., 2003).  
 
Figure 1.2 In silico drug screening flowchart 
How strong a compound binds into the active site is dependent on what kind of 
interactions the compound forms with the protein, how many interactions it makes, 
its desolvation energy and ultimately what the free energy of binding is. This is 
predicted using a mathematical algorithm, also called the “scoring function”. Each 
docked compound can be ranked and compared by the docking score (Coupez and 
Lewis 2006). Each docking program has its own calculation of the score (Feher and 
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Williams 2010; Pencheva, et al., 2010; Abreu, et al., 2012). The hits with the best 
score will then be either synthesized or bought for biological testing. The same 
principle can be used for the lead optimization process. The modified lead 
compounds are docked into the active site and then scored and ranked. Only the 
modification which gave a higher score will then be tested in a biological screen.  
The disadvantages of in silico screening are certainly the many false positives and 
negatives (Ekins, et al., 2007; 2007). It is still not possible to predict protein 
flexibility, molecule conformation and promiscuity perfectly due to the accurate 
calculation of the binding energy. The other problem is, that not all molecules, that 
could be found by in silico screening are available for testing. For this reason mostly 
only compounds, which are already commercially available are screened.  
1.1.3.1 Docking program DOCK3.5.54 
In this thesis mainly the docking program DOCK3.5.54 (Lorber and Shoichet 2005) 
was used for SBVS. It is a variation of DOCK, which was initially created in the 1980s 
by the Kuntz group and was the first docking program available (Kuntz, et al., 1982).  
Placing a ligand into an enzyme is a challenging task considering the degree of 
freedom of the ligand and the enzyme. Even when the ligand is considered to be 
rigid, it has already a degree of freedom of 6. And if the flexibility of ligand and 
protein is considered additionally with every rotated bond, the degree of freedom 
9 
 
 
 
increases exponentially, so therefore the systematic exploitation of all possible 
binding modes is computationally not feasible for a docking review. 
The docking program would have to be able to dock all possible orientations and 
conformations of the ligand, considering translation and rotation. To simplify this 
task, DOCK3.5.54 considers the protein as static. The pre-generated conformers (for 
example using OMEGA (Hawkins, et al., 2010)) are then superimposed on a 
common ring fragment (usually an aromatic ring system)(Lorber and Shoichet 
1998). Next, matching spheres are placed into the binding site of the protein. 
Subsequently, DOCK3.5.54 places the fragments onto the sphere centre, so that the 
fragment atoms are as close as possible to the sphere centres. Together they are 
used to generate a translational-rotational matrix which allows the fragment to be 
oriented in the binding site and with it the pre-calculated conformers.  
DOCK3.5.54 uses a force-field-based scoring function (Equation 1.1), which contains 
terms of electrostatic Energy (Eelec), van der Waals (Evdw) and the correction for 
ligand desolvation energy (ΔGdesolv) (Wei, et al., 2002; Graves, et al., 2005; Lorber 
and Shoichet 2005). 
 =  + 	 + ∆ 
Equation 1.1 Scoring function used in DOCK3.5.54 
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1.2 Human African trypanosomiasis (HAT) 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a 
pandemic parasitic disease found in the sub-Saharan Africa where it threatens 
millions of people in 36 countries. This fatal disease belongs to one of the most 
neglected diseases and is mostly prevalent in rural areas (Balasegaram, et al., 2008; 
Simarro, et al., 2011). Its prevalence has changed in the last 100 years. In the 1960s, 
transmission was practically interrupted in all endemic areas because of control and 
intervention programs (Brun, et al., 2010). The rarity of cases led to lower interest 
in surveillance and caused the disease to re-emerge in 1980s (Simarro, et al., 2011). 
For this reason a non-profit drug research and development organization DNDi 
(Drugs for Neglected Diseases Initiative) was established (Balasegaram, et al., 2008; 
Chatelain and Ioset 2011) to develop new treatments for the most neglected 
diseases like leishmaniasis, chagas disease, malaria and HAT.  
HAT is transmitted by the tsetse fly (Glossina spec.) and is caused by two subspecies 
of Trypanosoma brucei (T. brucei or Tb), the T. brucei gambiense (West Africa) and 
T. brucei rhodesiense (east Africa) (Fevre, et al., 2008). The symptoms of HAT 
depend on the subspecies and the stage of infection. Initially it starts with fever, 
headache, joint pains and itching and later listlessness, disordered sleep and 
neuromuscular dysfunction (Stich, et al., 2002; Checchi and Barrett 2008; Courtin, et 
al., 2008; Fevre, et al., 2008; Brun, et al., 2010; Malvy and Chappuis 2011). There 
are two stages of infection, firstly the haemolymphatic stage, where T. brucei enters 
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the blood stream and the lymph system, where it replicates. The second stage is the 
meningo-encephalitic stage, where the parasite invades the central nervous system. 
In addition, T. brucei gambiense is characterized by a chronic progression with an 
average duration of around 3 years and can be mistaken for a chronic haemopathy 
condition (Malvy and Chappuis 2011). T. brucei rhodesience disease on the other 
hand presents usually in an acute illness and leading to death within months. Most 
non-endemic cases of HAT are T brucei rhodesience diseases (Migchelsen, et al., 
2011; Simarro, et al., 2012). With 94 reported cases from 2000 to 2010 outside the 
endemic areas, HAT represents also a risk for travellers and migrants (Simarro, et 
al., 2012).  
Untreated HAT always leads to coma and death. There are four main drugs, which 
are currently used for HAT treatment (Figure 1.3). All of them have significant 
limitations due to toxicity, administration and treatment regimes. No new chemical 
drug has been approved since eflornithine in 1990 (Jacobs, et al., 2011). The only 
breakthrough so far was a combination treatment with nifurtomox/eflornithine 
(NECT) which was less toxic than eflornithine alone and easier to administer. 
Pentamidine and suramin are available for early-stage T. brucei gambiense disease. 
None of the drugs can cross the blood-brain barrier and are therefore useless for 
second stage treatment. Pentamidine reduces the mitochondrial membrane 
potential and binds to nucleic acids. It must be given intramuscularly and can cause 
hypotension (low blood pressure), hypoglycemia (diminished levels of glucose in 
blood), leukopenia (decreased number of white blood cells), hepatitis (liver 
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inflammation), nephrotoxicity (kidney poisoning) and pancreatitis (inflammation of 
the pancreas) (Kappagoda, et al., 2011). Suramin inhibits multiple trypanosome 
metabolic enzymes. Due to its toxicity it is only given as a second-line treatment. 
Suramin can cause exfoliative dermatitis (erythema and scaling of the skin), 
neuropathy (damage to nerves) and fatal hypersensitivity reaction (body reacts with 
an exaggerated immune response). For the second stage only eflornithine and 
melarsoprol are used. Eflornithine inhibits ornithine decarboxylase. It is less toxic 
than melarsoprol but also less reliable against T. brucei rhodesiense. The side effects 
could be fever, rash, peripheral neuropathy and diarrhoea. The mostly used drug 
against the second HAT stage is melarsoprol, despite its highest toxicity. 
Melarsoprol causes in 5 – 10% of the patients an encephalopathy which is in half of 
the cases fatal. It also causes fever, thrombocytopenia, abdominal pain and 
vomiting.  
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Figure 1.3 Drugs currently used for HAT treatment 
The insufficiency of the current drugs and treatment of HAT shows clearly, that 
new, safer and more effective drugs are badly needed. 
1.3 T. brucei 6-phosphogluconate dehydrogenase (Tb6PGDH) as a 
target for HAT 
The pentose phosphate pathway (PPP) (Figure 1.4 oxidative part) is present in most 
species (also humans) and is another key pathway of glucose metabolism (Duschak 
2011; Leroux, et al., 2011; Maugeri, et al., 2011; Stern, et al., 2011). The enzyme 
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6PGDH catalyse the conversion of 6-Phosphogluconate (6PG) to Ribulose-5-
phosphate (Ru5P) by generating NADPH and CO2. 
Using a drug target that is present in parasite and mammalian cells seems at first 
glance not to be a good choice. Nevertheless, it has been demonstrated in case of 
the key glycolytic enzyme glyceraldehyde-3-phosphatedehydrogenase (GAPDH) that 
differences in the binding site of coenzyme NAD+ are sufficient to selectively inhibit 
trypanosomatid enzymes (Aronov, et al., 1999).  
 
Figure 1.4 Oxidative phase of the pentose phosphate pathway 
In italic are the enzymes involved in the reaction and in bold the sugar educts 
and products.  
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Two NADP+ dependent enzymes of PPP, glucose-6-phosphate dehydrogenase 
(G6PD) and 6-phosphogluconate dehydrogenase (EC 1.1.1.44) have a major function 
in most organisms. They generate the reduced coenzyme NADPH which protects 
the organism against oxidative stress and is essential for a variety of reductive 
biosynthetic reactions, such as lipid production. A G6PD deficiency in humans 
causes haemolytic anaemia, an abnormal breakdown of red blood cells. The PPP 
was also determined to be present in both cultured procyclic and bloodstream 
forms of T. brucei (Cronin, et al., 1989). Sequence analysis has shown, that the 
enzyme 6PGDH had an unusual evolution in T. brucei and was only distantly related 
to the one in mammals (Barrett and Le Page 1993). The differences were evident by 
the fact, that trypanocidal drugs melarsoprol, cymelarsan and suramin were more 
potent against Tb6PGDH than against the mammalian enzyme (Hanau, et al., 1996). 
The enzyme Tb6PGDH was validated as a drug target using RNA interference 
technology (Bastin, et al., 1998; Craig, et al., 1998; Fire, et al., 1998) to switch off 
the gene encoding 6PGDH (Hanau, et al., 2004). This led to an accumulation of the 
substrate 6-phosphogluconate (6PG) which itself is an inhibitor of the key glycolytic 
enzyme phophoglucose isomerase in the second step of the Embden-Meyerhof 
glycolytic pathway (Rovere and Gastaldi 1967; Marchand, et al., 1989). As a 
consequence more 6-phosphate enters the PPP and increases the production of 
6PG even more. This positive feedback loop is fatal for T. brucei, because of its 
dependence on the glycolysis pathway for energy production. Furthermore, the 
parasite would not produce enough NADPH to protect itself against oxidative stress 
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and to generate carbohydrate intermediates used in nucleotide and other 
biosynthetic pathways. Tb6PGDH was chemically validated using analogues of high-
energy intermediates and transition-state analogues. Both were able to selectively 
inhibit this drug target (Dardonville, et al., 2004) (Figure 1.5).  
 
Figure 1.5 Mechanism of 6PGDH reaction and intermediate analogues 
Mechanism was adopted from (Wang and Li 2006). Lysine serves as a base and 
glutamine as acid in this reaction mechanism (Karsten, et al., 1998). 
A number selective inhibitors for Tb6PGDH were found and optimized (Bertelli, et 
al., 2001; Pasti, et al., 2003; Ruda, et al., 2007; Ruda, et al., 2010). A virtual 
fragment screening which addressed the phosphate binding site of 6PGDH 
identified several fragments with high ligand efficiencies and IC50 values in the low 
micro molar range (Ruda, et al., 2010). However, the binding modes of the 
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compounds have not been determined. Therefore, it is unclear how they bind to the 
enzyme, hindering their optimization. The crystal structure of 6PGDH is currently 
known for fourteen different organisms including Tb (Phillips, et al., 1998), 
Geobacillus stearothermophilus (Gs) (Cameron, et al., 2009), Lactococcus lactis 
(Sundaramoorthy, et al., 2007) and recently from homo sapiens (PDB 2JKV)(to be 
published). 
1.4 T. brucei UDP-glucose pyrophosphorylase (TbUGP) as a target 
for HAT 
It was shown, that glycoproteins are crucial for the survival, infectivity and de novo 
biosynthesis of sugar nucleotides of the parasites (Turnock and Ferguson 2007). The 
sugar nucleotides uridine-diphosphate galactose (UDP-Gal) (Roper, et al., 2002; 
Roper, et al., 2005; Urbaniak, et al., 2006), UDP-N-acetylglucosamine (UDP-
GlcNAc)(Stokes, et al., 2008) and GDP-fucose (GDP-Fuc) (Turnock, et al., 2007) have 
been shown by mutation studies to be essential for parasites growth. The 
nucleotides are the primary source of sugar for most glycosylation reactions. They 
can be formed either in the salvage pathway, by recycling existing sugar/sugar 
nucleotides that were formed during degradation of RNA/DNA or in de novo by 
biosynthesis of complex molecules from simple molecules like sugar or amino acids.  
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The sugar nucleotide UDP-Glc (Figure 1.6) is the donor of glucose in many different 
pathways and in Tb crucial in the synthesis of several glucose containing glycolipids, 
glycoproteins and a variety of secondary metabolites (Flores-Diaz, et al., 1997).  
 
Figure 1.6 Chemical structure of UDP-Glc 
Furthermore it plays an important role for the “quality control” of newly 
synthesized glycoproteins in the endoplasmic reticulum (Hammond and Helenius 
1995).  
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Figure 1.7 Summary of the sugar nucleotide biosynthesis pathway in T. brucei 
Sugar nucleotide biosynthesis pathway for Tb adopted from (Turnock and 
Ferguson 2007). The sugar nucleotides used for glycoconjugate biosynthesis in 
bold. Salvage pathways are in italics. Glc = Glucose; Glc6P = Glucose-6-
Phosphate; F6P = Fructose-6-Phosphate; GlcN6P = Glucoseamine-6-Phosphate; 
GlcN = Glutamine; GlcNAc6P = N-Acetyl-Glucosamine 6-Phosphate; GlcNAc1P = 
N-Acetyl-Glucosamine 1-Phosphate; UDP-GlcNAc = UDP-N-acetyl-Glucosamine; 
M6P = Mannose-6-Phosphate; M1P = Mannose-1-Phosphate; GDP-Man = 
Guanosine Diphosphate Mannose; GDP-Fuc = Guanosine Diphosphate Fucose; 
Glc1P = Glucose-1-Phosphate; UDP-Glc = UDP-Glucose; UDP-Gal = UDP-
Galactose. The numbers stand for the following enzymes: 1 = Hexokinase; 2 = 
Glucose-6-phosphate isomerase; 3 = Glucosamine-fructose-6-phosphate 
aminotransferase; 4 = Glucosamine-phosphate N-acetyltransferase; 5 = 
Phosphoacetylglucosamine mutase, 6 = UDP-N-acetylglucosamine 
pyrophosphorylase; 7 = Phosphomannose isomerase; 8 = 
Phosphomannomutase; 9 = Mannose-1-phosphate guanyltransferase; 10 = GDP-
mannose 4,6-dehydratase; 11 = GDP-L-fucose synthetase; 12 = 
Phosphoglucomutase; 13 = UDP–glucose pyrophosphorylase; 14 = UDP-
galactose 4-epimerase. 
Moreover, UDP-Glc is presumably a donor for the modified DNA base β-D-glucosyl-
hydroxymethyluracil, called J. The base J has been found in Tb in the 70-basepair 
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repeats and variant surface glycoprotein (VSG) gene of the telomeric FSG gene 
expression sites (van Leeuwen, et al., 1997; van Leeuwen, et al., 1998). This VSG is a 
protective coat of 5x106 GPI-anchored homodimers that helps the parasite to 
undergo the immune attack of the host by replacing the VSG coat by antigenetically 
different VSG molecules (Borst, et al., 1996; Cross 1996). As shown by Urbaniak, 
Turnock et al., (2006) knockout studies, the galactose metabolism is essential for 
the survival of Tb. The only way for Tb to synthesise galactose is by epimerisation of 
UDP-Glc to UDP-Gal by UDP-galactose 4-epimerase (Figure 1.7, enzyme 14). By 
interrupting the production of UDP-Glc by inhibiting TbUGP (EC 2.7.7.9), the 
parasite dies after 96 hours.  
Biosynthesis of UDP-Glc in Tb follows an ordered mechanism (Figure 1.8). First UTP 
binds to TbUGP and is stabilised by Mg2+ followed by the binding of Glc-1P and the 
reaction into UDP-Glc and pyrophosphate (PPi). This was confirmed by SPR, where 
the binding of Glc-1P could only be measured, when UTP was added into the 
running buffer (Hopkins, Navratilova et al., unpublished results). 
 
Figure 1.8 Ordered reaction mechanism of TbUGP 
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Unfortunately still no drug-like inhibitors are known for TbUGP. The only inhibitor 
known for TbUGP is the non- hydrolysable UTP-analogue UTP-α-S (compound 7 
from Table 3.5). However, this compound is not drug-like. 
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1.5 Objectives 
1.5.1 Structure-based hit discovery for the key enzymes Tb6PGDH 
and TbUGP 
The aim of this thesis was it to use in silico and experimental methods to identify 
novel, active, fragment-like compounds for two validated targets, Tb6PGDH and 
TbUGP (1.3 and 1.4), against HAT. To achieve this, fragment-libraries were screened 
for hit compounds using NMR. Further, structure-based virtual screening was used 
to screen a large library of commercially available compounds for TbUGP inhibition. 
To cover more chemical space, hit-discovery for TbUGP was complemented by a 
biochemical screen of a lead-like library with over 72 000 compounds. 
1.5.2 Hit validation, SAR and evaluation of binding mode of 
discovered hits 
Potential hits, discovered by in silico screening and experimental screening efforts, 
were further validated using biophysical methods such as SPR and NMR. These 
methods were used in order to characterize potency, competitive binding and 
selectivity of the preselected hits. Furthermore, the aim was to unravel the binding 
mode of the inhibitors and SAR using mutation studies and crystallography. 
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2 Hit discovery for 6PGDH 
2.1 Material and Methods 
All chemicals and reagents where purchased from Sigma-Aldrich, unless otherwise 
stated. Virtual screening compound 1 was purchased from Chembridge, 2 from 
LABOTEST and 3 from Enamine. 
2.1.1 Overexpression and purification of Gs6PGDH 
Table 2.1 Sequence of His-tagged Gs6PGDH 
HHHHHHSSGLEVLFQGPGHMAKHQIGVIGLAVMGKNLALNIESKGYSVAVYNRLREKTDEFL
QEAKGKNIVGTYSIEEFVNALEKPRKILLMVKAGAPTDATIEQLKPHLEKGDIVIDGGNTYFKDT
QRRNKELAELGIHFIGTGVSGGEEGALKGPSIMPGGQKEAHELVRPIFEAIAAKVDGEPCTTYIG
PDGAGHYVKMVHNGIEYGDMQLIAEAYFLLKHVLGMDAAELHEVFADWNKGELNSYLIEITA
DIFTKIDEETGKPLVDVILDKAGQKGTGKWTSQNALDLGVPLPIITESVFARFLSAMKDERVKAS
KVLAGPAVKPFEGDRAHFIEAVRRALYMSKICSYAQGFAQMKAASEEYNWNLRYGDIAMIFR
GGCIIRAQFLQKIKEAYDRDPALSNLLLDSYFKDIVERYQDALREIVATAAMRGIPVPGSASALAY
YDSYRTAVLPANLIQAQRDYFGAHTYERVTKKAIPHTEWLK 
 
 
 
24 
 
 
 
Table 2.2 Biochemical properties of His-tagged Gs6PGDH 
Number of amino acids: 488 
Molecular weight: 54017.9 
Theoretical pI: 6.44 
Abs 0.1% (=1 g/l): 0.989 at 280 nm (Artimo, et al., 2012) 
 
Table 2.3 Sequence of cleaved Gs6PGDH (crystallization construct) 
IESKGYSVAVYNRLREKTDEFLQEAKGKNIVGTYSIEEFVNALEKPRKILLMVKAGAPTDATIEQL
KPHLEKGDIVIDGGNTYFKDTQRRNKELAELGIHFIGTGVSGGEEGALKGPSIMPGGQKEAHEL
VRPIFEAIAAKVDGEPCTTYIGPDGAGHYVKMVHNGIEYGDMQLIAEAYFLLKHVLGMDAAEL
HEVFADWNKGELNSYLIEITADIFTKIDEETGKPLVDVILDKAGQKGTGKWTSQNALDLGVPLPI
ITESVFARFLSAMKDERVKASKVLAGPAVKPFEGDRAHFIEAVRRALYMSKICSYAQGFAQMK
AASEEYNWNLRYGDIAMIFRGGCIIRAQFLQKIKEAYDRDPALSNLLLDSYFKDIVERYQDALREI
VATAAMRGIPVPGSASALAYYDSYRTAVLPANLIQAQRDYFGAHTYERVTKKAIPHTEWLK 
 
Table 2.4 Biochemical properties of cleaved Gs6PGDH 
Number of amino acids: 448 
Molecular weight: 49724.9 
Theoretical pI: 6.01 
Abs 0.1% (=1 g/l): 1.074 at 280 nm (Artimo, et al., 2012) 
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Procedure 
Gs6PGDH was overexpressed and purified as described by (Cameron, et al., 2009). 
In brief, a Gs6PGDH full length ORF, cloned into a modified pET15b vector with N-
terminal hexa-histidine tag coupled to a Tobacco Etch Virus (TEV) protease 
recognition site was used. The expression was performed in Bl21(DE3)pLysS cells. 
Therefore, a single colony was grown with constant shaking (200rpm) in auto-
induction media (see Recipe for auto-induction media, page 115, appendix) 
supplemented with 50 mg/l carbenicillin, for approximately 2 h at 37 °C, followed by 
a second incubation step for 22 h at 22 °C. Cells were harvested by centrifugation 
(3500 g, 20 min, 277 K on BECKMAN J6-MC) and subsequently resuspended in 
resuspension buffer A (50 mM Tris-HCl pH 7.4, 250 mM NaCl, 50 µg Dnase, 50 µg 
lysozyme and EDTA-free protease inhibitor cocktail (Roche) according to 
manufactures instructions). In the next step the cells were disrupted by sonification 
and centrifuged (50,000 g, 30 min, 277 K on BECKMAN Avanti-J25) to separate the 
cell extract and the membrane pellet. The Supernatant was filtered and applied to a 
HisTrap HP 5 ml column using an ÄKTA-purifier.  
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Figure 2.1 Chromatogram of Gs6PGDH on a HisTrap HP 5 ml column 
The chromatogram displays the UV absorbance on the y-axis in blue in mAU, 
volume on the x-axis in ml, in green a gradient of imidazole in buffer A, in 
brown is the conductivity of the solution and in red the collection tubes. The 
SDS-page gel on the right shows the following from left to right: ft = flow 
through HisTrap with buffer A, protein ladder in kDa (SeeBlue), samples from 
tubes A5, B12, B3. Protein collected from A5-B3 for further purification. 
Retained His-tagged protein was eluted by a gradient of imidazole starting from 0 to 
1 M buffer B consisted of buffer A with 1 M imidazole. The eluted protein was 
cleaved for 2 h at 30 °C by adding 1 mg TEV protease (lab produced) per 15 mg 
6PGDH and dialysed in buffer A overnight at 4 °C. Next, 6PGDH was applied to a His-
Trap column to remove uncleaved protein.  
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Figure 2.2 Chromatogram of Gs6PGDH on a HisTrap HP 5 ml column after TEV – 
cleavage 
The chromatogram displays the UV absorbance in blue, in green a gradient of 
imidazole in buffer A, on the y-axis in brown is the conductivity of the solution 
in mS/cm and in red the collection tubes. Fractions that were analyzed by SDS-
page are labeled in the chromatogram accordingly. The SDS-page gel on the 
right shows the following from left to right: ctrl = defrosted, TEV - cleaved and 
purified 6PGDH enzyme as a control; samples from tubes A6, A10, C5 which 
were eluated without imidazole; protein ladder in kDa (SeeBlue) in the middle; 
D5 = uncleaved protein; TEV = cleaved TEV - Tag  
 
The elution containing cleaved protein in the resuspension buffer was subsequently 
purified using a Superdex 75 16/60 column.  
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Figure 2.3 Chromatogram of Gs6PGDH on a Superdex 75 16/60 column after TEV – 
cleavage 
The chromatogram displays the UV absorbance on the y-axis in blue in mAU, 
volume on the x-axis in ml, the conductivity of the solution in brown and in red 
the collection tubes. Fractions that were analyzed by SDS-page are labeled in 
the chromatogram accordingly. The SDS-page gel on the right shows the 
following from left to right: ctrl = defrosted, TEV - cleaved and purified 6PGDH 
enzyme as a control; sample from tube B5; protein ladder in kDa (SeeBlue)  
Next, the pure protein was dialysed into crystallisation buffer C (50 mM Tris-HCl pH 
7.4, 20 mM NaCl) and concentrated up to 12 mg/ml using VIVASPIN20 10,000 
MWCO (from SartoriusStedim biotech). Aliquots were flash frozen in liquid nitrogen 
and stored at -20 °C.  
Absorbance was measured at 280 nm to determine the enzyme concentration using 
a NanoVue Spectrophotometer. Enzyme concentration was calculated using the 
Beer-Lambert law: 
 =∈  
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where	 = , ∈= 			[ ∗ "# ∗ "#] , 
 = %ℎ	'ℎ = 1 and  = 	 
The molar extinction coefficient was calculated based on the enzyme sequence 
(Table 2.3) using the ExPASy server (Table 2.4) (Artimo, et al., 2012). 
2.1.2 NMR fragment screen 
The NMR fragment screen was carried out in collaboration with Daniel Fountaine 
(honours Student) who prepared the samples for screening. All spectra were 
acquired using a Bruker Avance 500 MHz Spectrometer with a 5 mm TXi cryoprobe 
at 298 K. For saturation transfer difference (STD) experiments (Meyer 1999; 1999) 
the sample was irradiated at 0.5 ppm. Water suppression was achieved by 
excitation sculpting (T.L. Hwang 1995). The wLOGSY experiment was carried out 
using ePHOGSY-NOE, a selective excitation with a 180° shaped pulse at the H2O 
position or at another frequency based on a sequence written by Claudio Dalvit 
(Dalvit and Böhlen 1996; 1996; Dalvit, et al., 2000; Dalvit 2009). The sample volume 
was a 500 µl aqueous suspension of 10 µM protein in phosphate buffer (10 mM 
Na2PO4, 1.76 mM KH2PO4) pH 7.5, 50 mM NaCl, 0.5 mM compound (dissolved in 
DMSO-d6) and 50 µl D2O. In total 12 fragment compounds were mixed per tube and 
tested at once. As controls the reference spectra of the compounds were compared 
to the spectrum from the compound-mix in each tube. Subsequently, to test for 
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competition, the substrate 6PG was added in excess (1.25 mM) to the mixture and 
the spectra were recorded again.  
2.1.2.1 NMR analysis 
The spectra were analysed manually using TOPSPIN 2.1. First, the 1H – spectrum 
was compared with each compound´s reference 1H - spectrum to ensure every 
compound added was present. Then the 2D spectrum from the STD experiment was 
separated into two 1H – spectra (in-house script) and analysed. Every signal found 
was compared to the 1H reference spectrum. If a compound signal was present in 
the STD experiment, it was further analysed if it was shown as a binder in the 
wLOGSY spectrum. A compound was only considered a hit if:  
• It had a signal in STD experiment  
• It was shown to bind  in the wLOGSY experiment  
• It had a signal reduction in both experiments when 6PG was added 
2.1.3 Kinetic characterisation of Gs6PGDH  
All kinetic assays were carried out on a SPECTRA max 340PC (Molecular Devices). 
For all kinetic studies the His-Tag cleaved crystallisation construct (Table 2.3) was 
used. 
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For kinetic characterisation of Gs6PGDH a colorimetric assay was used, where the 
absorption of product NADPH at 340 nm was measured over time. The buffer was 
an aqueous mixture of 50 mM Tris – HCl at pH 7.4, 1 mM DTT, 250 mM NaCl and 
0,02% CHAPS. The slope of the linear phase of each absorption curve was measured 
using a linear regression curve from Microsoft Excel where R2 was > 0.9.  
2.1.3.1 Assay development 
To be able to accurately determine the inhibition of compounds the dose-response 
curve must be linear over the observed time frame. Because Gs6PGDH is from a 
thermophilic organism, all biochemical assays were performed at 30° C. At this 
temperature the reactivity of Gs6PGDH gave a sufficient signal to noise ratio (Figure 
2.4) and the assay was easier to handle on the available instrument than at higher 
temperatures.
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Figure 2.4 Temperature screen of Gs6PGDH 
Time in minutes on x - axis versus absorbance at 340nm in atomic units (AU) on 
the y – axis is plotted at different temperatures. The blue curve was recorded at 
30 ° C, red at 35° C, green at 40° C and purple at 45° C.  
First, a NADP+ standard curve was measured (Figure 2.5) to make sure that the 
measured signals linearly depends on the NADP+ concentration. 
 
Figure 2.5 NADP+ standard curve with a linear regression fit  
NADP+ concentration curve from 0 -100 μM on the x – axis versus absorbance at 
340 nm on the y - axis and standard deviation as error bars (N = 2) with an R² 
for the linear regression of 0.99. 
Further, the optimal Gs6PGDH concentration was determined by measuring the 
absorbance over time at different Gs6PGDH concentrations at fixed concentrations 
of 60 μM NADP+ and 400 μM 6PG (Figure 2.6).  
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Figure 2.6 Reaction diagram at different Gs6PGDH concentrations 
Reaction diagram at different enzyme concentration with time in minutes on 
the x – axis versus absorbance at 340 nm on the y - axis. 
A Gs6PGDH concentration of 130 nM (Figure 2.6, green triangle) was found to result 
in a linear change in UV absorbance for 5 minutes and gave a sufficient signal to 
noise window for further measurements. Next, Michaelis - Menten kinetic was 
carried out to measure the affinity (Km) of the substrate 6PG and the velocity (Vmax) 
of the enzyme Gs6PGDH.  
) = *+,-[.]/+ + [.] 
Equation 2.1 Michaelis – Menten kinetic 
Where ) = reaction rate, [S] = substrate concentration, *+,-= maximum rate of 
enzyme at saturated substrate concentration, /+= Michaelis constant at which 
reaction rate is half maximum (substrate affinity). 
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) =
/+*+,-[.] +
1
*+,- 
Equation 2.2 Lineweaver-Burk linearization of the Michaelis-Menten equation 
 
Figure 2.7 Saturation curve of Gs6PGDH with Lineweaver–Burk plot 
Average saturation curve of Gs6PGDH from four measurements (N = 4) with 
substrate (6PG) concentration in μM on the x-axis and the reaction rate on the 
y–axis. As an insert a Lineweaver-Burk linearization (Equation 2.2) plot is 
shown. The x-intercept obtained by extrapolation of the positive experimental 
data is0 #12, #3245 is the y-intercept ( #[678] = 0) and 123245 is the slope of the line. 
The blue arrows indicate where  
As a result a Km  of 25 ± 4 μM was determined for the substrate 6PG with an Vmax of 
0.024 ± 0.0009 μM/min. The value for Km, Vmax and their associated errors are the 
mean values from four independent measurements (N = 4). 
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For the inhibition assay the following concentrations were used: 130 nM Gs6PGDH, 
25 µM 6PG (~ Km) and 120 µM NADP
+ (in excess). The assays were carried out at 30 
°C measuring absorption every 4 seconds until reaction was complete.  
For the dose response curves two equations were used to fit the data points (both 
equations as implemented in GraFit from Erathacus Software Limited): 
: = 100%1 + < =>?@A
 
Equation 2.3 Two parameter fit equation 
Where  = slope factor (gradient),  = cpd concentration, : = response.  
: = B'1 + < =>?@A
 + CD'EF 
Equation 2.4 Four parameter fit equation 
Where  = slope factor (gradient),  = cpd concentration, : = response, Range is 
the fitted uninhibited value minus the Background. Background = the minimum 
y value multiplied by 0.95. 
Equation 2.3 was used to fit data points which did not reach saturation at high 
inhibitor concentration or when not enough data points were available at high 
concentration. Otherwise, Equation 2.4 was used to fit the sigmoidal curve through 
the data points.  
2.1.4 Crystallisation of Gs6PGDH 
Crystals of Gs6PGDH were grown using the hanging drop method in 24-well plates 
on VDX slides (Hampton Research). 
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His-tag cleaved Gs6PGD (Table 2.3) was crystallised in two days in hanging drops 
consisting of 2.5 mM compound 1.(compound number 12 from the following paper 
(Ruda, et al., 2010)), 1 µl protein solution (12 mg/ml) and 1 µl reservoir 
(crystallisation buffer at pH = 7: 0.2 M sodium chloride, 2.5 mM NADP+ and 2 M 
ammonium sulphate as a precipitant) equilibrated against 500 µl of reservoir at 20 
°C as previously described (Cameron, et al., 2009). The compound had to be 
dissolved in water at pH = 7 and added to the crystallisation buffer in order for the 
crystals to grow. Any DMSO impurities prevented crystal growth. Crystals were 
flash-cooled in crystallisation buffer with 20% glycerol.  
2.1.4.1 Data collection, processing and structure modelling 
X-ray diffraction data for the Gs6PGDH enzyme were collected at beamline ID14-1 
in the European Synchrotron Radiation Facility (ESRF) in Grenoble (France), 
equipped with an ADSC Q210 CCD detector. A full data set of 720 images were 
collected from 321 ° - 141 ° with ɸ = 0.25 and 3 s exposure time. Crystal orientation, 
cell parameters and possible space group were determined using HKL2000 
(Otwinowski and Minor 1997). Generated reflection lists and integrated reflections 
from the images were scaled and merged using SCALA (Evans 2006; 2011) from the 
CCP4 suite of programs (Potterton, et al., 2003). Resolution data less than 38.8 or 
greater than 2.7 Å were excluded to produce an Rmerge of 0.131.  
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Model generation was done using PHASER (McCoy 2007; McCoy, et al., 2007). As a 
model enzyme the coordinates from Gs6PGDH (PDB 2W90) dimer were used as a 
starting point with a sequence identity set to 0.95 and a sequence file of the model 
enzyme 2W90. A solution was found with a rotation function score (RFZ) = 7.8 and a 
translation function score (TFZ) = 13.2. The structure was refined using REFMAC5 
(Murshudov, et al., 2011) from the CCP4 package. Refinement was using automatic 
weighting and local NCS restraints. Iterative model building was carried out using 
the interactive graphics program WinCOOT (v. 0.7.1 -pre) (Emsley and Cowtan 2004; 
Emsley, et al., 2010). At first, all amino side chains with no electron density were 
mutated as stubs and after a refinement with REFMAC5 the amino side chains were 
mutated back and the occupancy of the atoms without electron density were set to 
0.01. The structure was refined using the validation steps available in WinCoot and 
checked using web-based validation server MolProbity 
(http://molprobity.biochem.duke.edu/) (Chen, et al., 2010) and RCSB PDB 
(http://validate.rcsb.org/). 
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2.2 Results 
2.2.1 Structure analysis of 6PGDH enzymes 
In the protein databank only one structure of Tb6PGDH (PDB 1PGJ) (Phillips, et al., 
1998) can be found (updated December 2013). This is due to its instability and 
therefore difficulties of overexpression and purification. For this reason the 
homologue enzyme Gs6PGDH was used for hit discovery due to its stability and 
binding site similarity. The binding sites of 6PGDH are highly conserved among 
species (Figure 2.8, Table 2.5). 
 
Figure 2.8 Sequence alignment of 6PGDH enzymes from different species 
Sequence alignment from top: Homo sapiens (h6PGDH), Geobacillus 
stearothermophillus (Gs6PGDH) and Trypanosoma brucei (Tb6PGDH). Identical 
amino acids are marked with a red background. Residues, which form a 
hydrogen bond to 6PG in the crystal structure 2W90 are marked with a green 
box and the ones that form a hydrogen bond to NADP+ with a blue box. 
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Sequences were aligned using the web-based program ClustalW2 from the 
EMBL-EBI webpage (http://www.ebi.ac.uk/Tools/msa/clustalw2/)(Larkin, et al., 
2007). Similarity colouring was done using the web-based program ESPript 2.2 
(http://espript.ibcp.fr)(Gouet, et al., 2003). 
Table 2.5 Sequence identity of 6PGDH enzymes from different species 
Name 
Length 
amino acids 
Name 
Length 
amino acids 
Identity in 
% 
Gs6PGDH 470 Tb6PGDH 478 36 
Gs6PGDH 470 h6PGDH 483 56 
Tb6PGDH 478 h6PGDH 483 32 
 
Comparison of Gs6PGDH and Tb6PGDH sequences revealed residues conservation 
for the N-terminal, central and tail domains to 49 %, 26 %, 44 % respectively. The N-
terminal and the tail domain contribute to the creation of the active site and show 
the highest level of conservation. The central domain contributes to dimer 
formation and is less well conserved. All structures of 6PGDH that are currently 
found in the protein database are dimers. The substrate 6PG does make defined 
hydrogen-bond interaction in the conserved binding site. The 6PG phosphate is 
accepting hydrogen bonds from Tyr190, Lys260 and Arg287. The hydrogen-bond 
interactions with Asn186, Thr262 (water mediated), Asn102, Ser128, Gly129 and 
Gly130 are holding the ligand in place. Two amino acids, which are important for 
the enzyme mechanism, Lys182 (Zhang, et al., 1999) and Glu189 (Karsten, et al., 
1998), are also important for ligand binding (Figure 2.9).  
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Figure 2.9 Gs6PGDH interactions with the substrate 6PG 
In pink are the interacting Gs6PGDH amino acids making hydrogen bonds (white 
dots) to 6PG (lightblue carbon atoms). For clarity water mediated interactions 
are not shown. 
For a better comparison of the NADP+ binding sites of Gs6PGDH, Tb6PGDH and 
h6PGDH, homology models of the enzymes were created using the online pipeline 
SWISS MODEL (http://swissmodel.expasy.org/)(Arnold, et al., 2006). As a result of 
the algorithm in the underlying homology building program, whenever possible, the 
backbone of the build homology models traces exactly that of the template and 
positions of conserved amino acid side chains are not optimized in the models. For 
the purpose of analysing the NADP+ binding sites this has the advantage that 
differences in the amino acid residues can be easily spotted by visual examination 
(Figure 2.11). 
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Figure 2.10 Overlay of the NADP+ binding pocket from h-, Gs- and Tb6PGDH 
Carbon atoms of h6PGDH are marked in grey, of Gs6PGDH in light blue and of 
Tb6PGDH in green. The carbon atoms of cofactor NADP+ is showed in yellow 
with hydrogen bonds (shown as white dots) to h6PGDH residues (shown as grey 
text). For clarity the overlay shows only part of the pocked at 7 Å around NADP+ 
and only side chains of h6PGDH are shown. 
The overlay of h6PGDH and the homology models of Gs6PGDH and Tb6PGDH show 
a perfect conservation of the backbone chain but reveal several differences in the 
side chains of the enzymes. All the different amino acids around NADP+ are shown 
in Figure 2.11 and listed in detail in Table 2.6. The NADP+ phosphate is accepting 
hydrogen bonds from Thr35, Lys38 and Arg34. The hydrogen-bond interactions with 
Phe84, Leu11, Val75, Met14, Val13, Asn103 and Gly451 are holding the co-ligand in 
place. 
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Figure 2.11 Overlay of the NADP+ binding pocket from h-, Gs- and Tb6PGDH 
showing differences of side chains. 
Carbon atoms of h6PGDH are marked in grey, of Gs6PGDH in light blue and of 
Tb6PGDH in green. For clarity the overlay shows the same orientation as Figure 
2.10 but without NADP+ and only the different side chains of h6PGDH are 
shown. For the corresponding amino acids of Gs- and Tb6PGDH see Table 2.6 
All amino acids with side chains oriented to NADP+ and which are different among 
the species can cause selectivity. For example the positively charged Lys76 in 
h6PGDH is Gln77 in Tb6PGDH which means, that a positive charged group is 
replaced by an uncharged side chain. The polar side chain of Gln79 in h6PGDH is a 
hydrophobic Ala80 of Tb6PGDH. Especially interesting is the difference of Phe84 in 
h6PGDH to Thr85 in Tb6PGDH. Here not only a hydrophobic side chain is changed to 
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a polar one, but also the aromatic ring system of Phe84 can do stacked interaction 
with the selective inhibitor.  
Table 2.6 Differences in side-chain - amino acids of h-, Tb- and Gs6PGDH at 7 Å 
around NADP+ 
h6PGDH Gs6PGDH Tb6PGDH 
Ile9 Ile11 Val7 
Ala12 Ala14 Gly10 
Gln16 Lys18 Ala14 
Phe32 Tyr33 Phe30 
Thr35 Leu36 Thr33 
Val36 Arg37 Tyr34 
Leu73 Leu73 Ile74 
Lys76 Lys76 Gln77 
Gln79 Ala79 Ala80 
Ala80 Pro80 Ala81 
Val81 Thr81 Thr82 
Asp83 Ala83 Ser84 
Phe84 Thr84 Thr85 
Gly101 Gly101 Thr102 
Ser104 Thr104 Ala105 
Val128 Val128 Ile129 
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Considering the fact, that the hydrogen-bond pattern of 6PG is conserved among 
species and that the cofactor site show several differences, the strategy was:  
1. To find compounds that bind into the 6PG binding site using 
Gs6PGDH as the thermo stable Model-enzyme 
2. To chemically modify the compound found by the first stage so that 
it will expand into the NADP+ pocket and bind selectively to Tb6PGDH 
exploiting the differences in the NADP+ binding site. 
It was previously shown that homologue enzymes can be used to study binding 
modes of Tb6PGDH inhibitors (Sundaramoorthy, et al., 2007). Sundaramoorthy et 
al., (2007) used Ll6PGDH to determine the binding mode of a HEI inhibitor (4) by 
using crystallisation methods.  
The substrate binding site conservation between Gs6PGDH and Tb6PGDH and its 
increased stability made Gs6PGDH a good model enzyme for hit discovery. 
Additionally, it was further shown, that Gs6PGDH can be crystallized and therefore 
used for X-ray binding mode determination of potential inhibitors.  
2.2.2 Inhibition assay with virtual screening hits 
A virtual screening was carried out previously (Ruda, et al., 2010) and from this, 18 
Tb6PGDH inhibitors were identified. The binding modes of these inhibitors were not 
determined, which would be a great help to establish a SAR and produce lead 
compounds. Therefore, the homologue enzyme Gs6PGDH was used to determine a 
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binding mode for the virtual screening hits. Additionally, the virtual screening hits 
should be kinetically tested for activity. Therefore, all virtual screening hits were 
tested against Gs6PGDH and the active compounds were planned to be tested 
against Tb6PGDH. As a control compound a high energy intermediate hydroxamate 
4 (Dardonville, et al., 2004) was chosen due of its low Ki of 0.01 µM for Tb6PGDH. 
 
Figure 2.12 Dose response curve of 1 
Dose-response curve with error bars for each data point from two experiments 
(each with n=2), percentage inhibition on y-axis and compound concentration in 
µM on x-axis (logarithmic scale). Points were fitted using a two parameter 
equation (Equation 2.3). Analysis from two experiments returns a pIC50 = 
3.69±0.02 and a Hill slope of 1.0 ± 0.1 (mean ± SD; N=2). 
Only three compounds out of 18 were found to inhibit Gs6PGDH (Table 2.7; 
compound 1 see Figure 2.12, compound 2 see Figure 2.13 and compound 3 see 
Figure 2.14). Except for compound 2, the pIC50 values were lower as the published 
ones for Tb6PGDH (Ruda, et al., 2010). For 1 a pIC50 of 3.69±0.02 (published 4.29 for 
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Tb6PGDH), for 2 a pIC50 of 4.37±0.05 (published 4.28 for Tb6PGDH) and for 3 a pIC50 
of 3.43±0.04 (published 4.36 for Tb6PGDH) (Figure 2.15). The largest discrepancy 
was found for the control compound 4. The published Ki of 4 for Tb6PGDH was 0.01 
µM, but the calculated Ki based on the measured IC50 value (Equation 3.3) for 
Gs6PGDH was 4.2±1.2 µM which is about four hundred times higher. 
 
 
Figure 2.13 Dose response curve of 2 
Dose-response curve with error bars for each data point from three 
experiments (each with n=2), percentage inhibition on y-axis and compound 
concentration in µM on x-axis (logarithmic scale). Points were fitted using a two 
parameter equation (Equation 2.3). Analysis from three experiments returns a 
pIC50 = 4.37±0.05 and a Hill slope of 1.0 ± 0.15 (mean ± SD; N=3). 
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Figure 2.14 Dose response curve of 3 
Dose-response curve with error bars for each data point from two experiments 
(each with n=2), percentage inhibition on y-axis and compound concentration in 
µM on x-axis (logarithmic scale). Points were fitted using a two parameter 
equation (Equation 2.3). Analysis from two experiments returns a pIC50 = 
3.43±0.04 and a Hill slope of 0.8 ± 0.00 (mean ± SD; N=2). 
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Figure 2.15 Dose response curve of 4 
Dose-response curve with error bars for each data point from two experiments 
(each with n=2), percentage inhibition on y-axis and compound concentration in 
µM on x-axis (logarithmic scale). Points were fitted using a four parameter 
equation (Equation 2.4). Analysis from two experiments returns a pIC50 = 
5.07±0.02 and a Hill slope of 0.8 ± 0.02 (mean ± SD; N=2). 
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Table 2.7 Inhibition data for virtual screening hits published in (Ruda, et al., 2010) 
# Structure 
published 
Tb6PGH 
IC50 converted 
to pIC50 
published 
Tb6PGH 
Hill slope 
Gs6PGDH 
pIC50  
Gs6PGDH 
Hill slope 
1 
 
4.29 1.7 3.69±0.02 1.0±0.1 
2 
 
4.28 4.8 4.37±0.05 1.0 ± 0.15 
3 
 
 
4.36 1.8 3.43±0.04 0.8 ± 0.00 
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Table 2.8 Inhibition data for high energy intermediate analogue as described by 
(Dardonville, et al., 2004) 
# Structure 
published 
Tb6PGH 
Ki [µM] 
published 
Tb6PGH 
Hill slope 
Gs6PGDH
a 
Ki [µM]  
Gs6PGDH 
Hill slope 
4 
 
0.01 N/A 4.2±1.2 0.8±0.02 
a Ki was based on the determinded IC50 value (Equation 3.3) for a better 
comparison to the published data. 
2.2.3 Determination of binding mode of virtual screening hits using 
crystallography 
The crystal structure of Gs6PGDH was crystallised with the inhibitors as described 
previously (Cameron, et al., 2009). The crystals only grew if compound 1 and NADP+ 
were present. Diffraction was calculated in-house on a Rigaku X-ray instrument with 
R-AXIS IV++ imaging plate with a resolution of 2.7 Å. Data for same crystal were 
collected at ESRF in Grenoble with a resolution of 1.8 Å (Table 6.3). After 
refinement, no electron density for the ligand was found.  
Virtual screening compound 1 was the only one that was suitable to further 
optimisation. Every attempt to crystallise Gs6PGDH without a ligand or just with 
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NADP+ was unsuccessful, so therefore no apo-crystals could be produced for ligand 
soaking. When compound 1 was dissolved in DMSO, no crystals could be grown 
under the same conditions as published by Cameron, S. et al., 2009. Only by 
adjusting the pH to 7, compound 1 could be solubilised in crystallisation buffer 
without DMSO. This adjustment allowed Gs6PGDH to crystallise in presence of 2.5 
mM 1 and 2.5 mM NADP+.  
2.2.4 Fragment screening using NMR methods 
The in-house fragment library containing 652 fragment-like compounds was 
screened for binding to Gs6PGDH as described (2.1.1). From this library 36 
compounds showed binding in both NMR experiments (STD and wLOGSY) and 
showed a signal reduction after adding 1.25 mM 6PG for competition. None of the 
36 compounds had a carboxylate group, which is surprisingly considering that all 
virtual screening hits found by Ruda, G.F. et al., (2010) were acids. Therefore, two 
acids (5 and 6) from the screen were also short-listed for further studies (Table 2.9). 
Acid 5 was a binder in STD and wLOGSY experiment, but a signal reduction after 
adding 6PG could not be seen in STD. The second acid 6 showed only binding in STD 
without a signal reduction with 6PG. Despite these hits, 100 other compounds 
showed binding in at least one of the experiments. That means that 20.9% (136 out 
of 652) of all screened compounds bound to Gs6PGDH, indicating a high false 
positive rate. This high rate can be explained in parts by the weak binding of 6PG to 
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Gs6PGDH (Km =25 µM) which makes it problematic to achieve competition with a 
potential inhibitor. An inhibitor in nM range would have been a more reliable 
indicator for the hit identification, but was unfortunately not available.  
Table 2.9 Active acids found by a fragment screening for Gs6PGDH 
# Structure 
5 
 
6 
 
 
2.2.5 Inhibition assay with NMR fragment hits 
All 38 NMR hits were tested for Gs6PGDH inhibition at 1 mM compound 
concentration in a biochemical assay which was previously described (2.1.3). Due to 
no or only weak inhibition at this concentration, it was not possible to measure a 
dose response curve for either of the compounds. Only 5 (PI = 50% at 1 mM) and 6 
(PI = 32% at 1 mM) were active at the chosen concentration (Table 2.9). All of them 
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were acids. The reason for this is unclear. However, this result is consistent with the 
published data (Ruda, et al., 2010). All compounds found by Ruda, et al., 2010 in a 
virtual screening were acids, too. Crystallisation trials with acids found by NMR 
fragment screening 
Two active acids (5 and 6 ) were set up for crystallization trials as previously 
described (2.1.4). Unfortunately none of the acids crystallised under the previous 
conditions.  
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2.3 Discussion 
2.3.1 Virtual screening hits 
Most virtual screening hits found by Ruda, G.F. et al., 2010 were not active against 
Gs6PGDH (Table 2.7). Unfortunately the publication does not mention important 
details on how the inhibition screen was carried out. This fact makes it difficult to 
evaluate Gs6PGDH as a model enzyme for Tb6PGDH. The following important 
questions should have been addressed: 
• At which temperature was the screen carried out? This is especially 
important to know, because of the instability of the Tb6PGDH enzyme as 
mentioned before (Phillips, et al., 1998; Sundaramoorthy, et al., 2007).  
• How many replicates were carried out (N = ?) and how was the error 
calculated? 
• What model was used to fit the parameters and how were they normalised?  
• Why the Hill slopes of all compounds, except for compound 13 (paper), were 
higher than 1? 
• Some of the compounds do absorb at 340 nm or interact with the assay. 
How was inhibition tested for such compounds? 
• What was used as a positive control for the inhibition? 
Here, for inhibition studies of Gs6PGDH the high energy intermediate 4 was used as 
a positive control. The published potency for this compound (Dardonville, et al., 
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2004) could not have been confirmed. The paper does as well not mention 
important points: 
• How was the stability of Tb6PGDH at 20° C ensured while the inhibition 
assay was carried out? 
• How many replicates were carried out (N = ?) and what is the error of Ki and 
IC50? 
As a conclusion two scenarios could be possible.  
1. The conserved 6PG binding site is not enough to translate the binding 
affinity of the compounds from Tb6PGDH to Gs6PGDH. It is also plausible 
that the compounds bind into the less conserved NADPH binding site instead 
of the 6PG site. Consequently there must be other structural factors than 
the hydrogen-bond interaction pattern, which causes the differences in 
binding affinities. While difficult to rationalise, such a behaviour has already 
been observed for other enzymes (Baba, et al., 2003; Cleghorn, et al., 2011; 
Teng, et al., 2013). Nevertheless, compounds 1, 2, 3 and 4 were confirmed 
as inhibitors, even though not as active as for Tb6PGDH.  
2. The published data on which this study was based on is not correct and 
needs to be reanalysed considering the questions addressed above. 
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2.3.2 Crystallisation and crystal structure determination 
The crystals diffracted at 2.7 Å in-house and at 1.8 Å at the synchrotron. The 
analysis of the X-ray structure showed no ligand in the active site. All previous 
crystallisation experiments have shown that crystals only appear in the present of 
the ligand or the substrate. One reason, that the ligand was not present in the 
crystal structure could be the transfer of the crystal from the mother liquor to 20% 
glycerol for cryo protection. Every direct transfer of the crystal to the 
cryoprotectant caused the crystal to dissolve. Therefore, a step-wise transfer to 
10%, 15% and 20% glycerol was necessary. Even though the ligand was present in 
each reservoir during the transfer, the low binding affinity may have caused the 
ligand to diffuse away from the crystal, especially as the cry-buffers are more 
hydrophobic than the buffer used for determining the affinity of the compounds. 
This reduces the contribution of the hydrophobic effect to binding affinity and is 
likely to result in weaker binding affinity in the cryo-conditions. 
2.3.3 Fragment NMR – screening and hit validation 
Our in-house compound library consisting of 652 diverse compounds was screened 
for binding affinity to Gs6PGDH using NMR. This approach identified 36 compounds 
able to bind the target protein in both experiments (STD and wLOGSY) with a 
decreasing signal after the addition of 6PG. From 38 selected compounds, only two 
acids were active at 1 mM in biochemical colorimetric assays which were selected 
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on a rational basis. One reason why 36 compounds were not confirmed by this 
method could be that they are all weak binders with an IC50 over 1 mM.  
Both actives compounds were acids (5 -> PI 50% and 6-> PI 32%). At concentrations 
≥ 500 µM the absorbance of the reaction solution with compound 5 increased, 
suggesting that either the compound absorbs at 340 nm or does react with NADP+ 
producing more NADPH.  
In summary, despite of all efforts, no binding mode could be determined of the 
virtual screening hits.  
The high polarity of the active site and the lack of confirmed, competitive inhibitors 
questions 6PGDH as a druggable enzyme, at least for a rational hit discovery 
approach. 
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3 Hit discovery for UGP 
3.1 Material and Methods 
All reagents, unless otherwise stated were purchased from Sigma Aldrich. 
Screening compounds 8, 9, 10 and 15 were purchased from Sigma Aldrich, 11 and 
13 from Apollo Scientific and 20, 21, 22 from (Otava, Ltd). 
3.1.1 Homology model 
Sequence alignments between TbUPG and hUGP were generated using ClustalW 
(Thompson, et al., 1994). Subsequently, Modeller 9.2 (Sali and Blundell 1993) was 
used to build homology models of hUGP, whereas the TbUGP crystal structure (PDB 
code 3GUE) served as a template. Modeller was run with default settings, and only 
the highest-scoring structure was used for further analysis and modelling.  
3.1.2 Virtual screening and molecular docking  
3.1.2.1 Compound database 
From an in-house database of 5.2 million commercial available compounds with 
precalculated physiochemical properties (Brenk, et al., 2008), only compounds 
which had the following properties were selected for virtual screening: 
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• Number of heavy atoms < 24 
• Rotational bonds ≤ 4 
• Number of hydrogen-bond acceptors ≥ 2 
• Number of hydrogen-bond donors ≥ 1 
3.1.2.2 Pharmacophore filter 
The compounds selected for virtual screening were further filtered by a 3D 
pharmacophore defined using Unity (Tripos Inc., St. Louis, MO). The compounds 
were first converted to a 3D UNITY database using default parameters and macro 
files. The 3D pharmacophore was derived based on the interactions of the uracil 
moiety of the substrate as found in the crystal structure TbUGP-substrate complex 
(PDB code 3GUE, Figure 3.1). Spheres with a 1.5 Å radiuses were placed around the 
positions of the nitrogen atom of the uracil moiety and the carbonyl groups to 
indicate locations of hydrogen donor and acceptor groups, respectively. To consider 
the directionality of the hydrogen bonds the groups were connected with spheres 
placed around the amino group of Gly189 (donor), the carbonyl group of Gln161 
(acceptor) and the amino group Gly83 (donor). Additionally to the hydrogen bond 
interactions a sphere indicating an aromatic group was placed at the centre of the 
uracil ring. 
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Figure 3.1 Schematic view of the 3D pharmacophore for potential TbUGP 
inhibitors 
Acceptor groups are deciphered as red cycles, donor groups as blue cycle, the 
aromatic feature is marked as a yellow circle and dotted lines indicate 
interactions between acceptor and donor groups. 
The hydrophobic feature and at least two out of the possible three hydrogen bond 
interactions were required to fulfil the pharmacophore. 
3.1.2.3 Receptor preparation for docking 
For docking, the software DOCK 3.5.54 (Lorber and Shoichet 1998; Wei, et al., 2002; 
Mysinger and Shoichet 2010) was used. The TbUGP structure with the coordinates 
(PDB code 3GUE) (Marino, et al., 2011) was used as receptor for docking. Hydrogen 
atoms were added using MOLOC (Gerber, molecular design) and their positions 
minimized using the MAB force field (Gerber and Muller 1995) as implemented in 
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MOLOC in presence of the product present in the structure, while keeping all non-
hydrogen atoms rigid. Subsequently, all ligands, water molecules and ions were 
removed from the crystal structure. The sphere set used to define the region of the 
binding site with a low dielectric constant, was created based on bound UDP-Glc 
(3GUE). The product UDP-Glc was modified by adding atoms to the 2-hydroxy group 
of ribose to completely fill the cavity. For the sphere set, used for placing the 
ligands into the binding site, the matching atoms were placed around the three 
functional groups of uracil groups that are part of the pharmacophore (Figure 3.1 
and Figure 3.2). Partial charges for all receptor atoms were obtained using the 
AMBER-99 force field parameters (Wang 2000). The electrostatic potential was 
calculated using DelPhi (Nicholls and Honig 1991), with a grid size of 65 and an 
internal dielectric constant of 2 and an external dielectric constant of 78. The van 
der Waals potential was calculated using a DOCK utility named CHEMGRID (Meng, 
et al., 1992; Shoichet, et al., 1992). Maps to calculate partial ligand desolvation 
were generated using SOLVMAP (Mysinger and Shoichet 2010).  
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Figure 3.2 Matching sphere set generated for UGP  
The green spheres indicate the positions of the matching points used for 
docking. The uracil ring is shown for clarity, where carbon atoms are indicated 
in light blue, nitrogen atoms in dark blue, oxygen atoms in red and part of the 
surrounding enzyme with white carbon atoms.  
3.1.2.4 Small molecule preparation and molecular docking 
DOCK 3.5.54 was used to dock small molecules flexibly in to the active site of 
TbUGP. The small compounds with pre-calculated physicochemical properties 
selected from the database (3.1.2.1), were filtered as described (3.1.2.2). All 
compounds were stored in SMILES format (Weininger 1988). The protonation- and 
tautomeric states for each compound were calculated using an in-house script 
based on the OEToolkit (Openeye, Santa Fe, NM). The 3D and multiple low energy 
conformations were generated using OMEGA2 (Openeye, Santa Fe, NM). AMSOL 
(http://comp.chem.umn.edu/amsol/; (Wei, et al., 2002)) was used to calculate the 
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desolvation energies and partial charges. Finally all ligands were aligned on their 
ring systems and stored in a hierarchical format (Wei, et al., 2002). 
The following settings were chosen to sample ligand orientations: ligand and 
receptor bins were set to 0.5 Å, and overlap bins were set to 0.4 Å; and the distance 
tolerance for matching ligand atoms to receptor matching sites ranged from 1.1 to 
1.2 Å. Only docking poses which did not placed any atoms in areas occupied by the 
receptor was scored for electrostatic interaction energy and van der Waals and 
complementarity (Lorber and Shoichet 1998) and penalized according to its 
estimated partial desolvation energy. For each compound, only the best-scoring 
database representation (tautomer, protonation state, multiple ring alignment) was 
stored in the final docking hit list. 
3.1.2.5 Docking analysis 
All docked compounds were visually inspected using Pymol (The PyMOL Molecular 
Graphics System, Version 1.5.0.4 Schrödinger, LLC). Only compounds which were 
placed in the uracil binding site and made at least two hydrogen bonds to the 
protein were selected for further investigations. If the compounds contained 
moieties exceeding the uracil binding site, it was required that they pointed into the 
cavity located opposite the 2-hydroxy group of the ribose in the TbUGP complex 
structure (Figure 3.8 a)). This was mandatory in order to search for selective 
compounds that would not inhibit hUGP. 
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3.1.3 Protein overexpression and purification of TbUGP 
Two different constructs A and B of TbUGP were used: For kinetic assays the 
“kinetic assay construct” A (Table 3.1) and for crystallisation the “crystallisation 
construct” B (Table 3.3). Both constructs were purified as described before (Marino, 
et al., 2010).  
Table 3.1 Amino acid sequence of TbUGP kinetic assay construct A 
MGSSHHHHHHSSGLEVLFQGPHMPLNPPSAFSGAALACLEKMQASGVEEKCIHIFLIQHALVR
KGETGYIPEKSISPVESLPFLQGIETKGENTALLRQAVVLKLNGGLGTGMGLNGPKSLLQVKNG
QTFLDFTALQLEHFRQVRNCNVPFMLMNSFSTSGETKNFLRKYPTLYEVFDSDIELMQNRVPKI
RQDNFFPVTYEADPTCEWVPPGHGDVYTVLYSSGKLDYLLGKGYRYMFISNGDNLGATLDVRL
LDYMHEKQLGFLMEVCRRTESDKKGGHLAYKDVIDETTGQTRRRFVLRESAQCPKEDEDSFQ
NIAKHCFFNTNNIWINLMELKKMMDEQLGVLRLPVMRNPKTVNPQDSQSTKVYQLEVAMG
AAISLFDRSEAVVVPRERFAPVKTCSDLLALRSDAYQVTEDQRLVLCEERNGKPPAIDLDGEHYK
MIDGFEKLVKGGVPSLRQCTSLTVRGLVEFGADVSVRGNVVIKNLKEEPLIIGSGRVLDNEVVV
VE 
Table 3.2 Biochemical properties of TbUGP kinetic assay construct A 
Number of amino acids: 507 
Molecular weight: 56857.1 Dalton 
Theoretical pI: 6.23 
Abs 0.1% (=1 g/l): 0.560 at 280 nm (Artimo, et al., 2012) 
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Procedure 
Cultures of E. coli BL21(DE3) cells containing a modified pET15B plasmid were 
grown in an incubator (INFORS HT Multitron) at 37 °C in LB medium supplemented 
with ampicillin (50 µg/ml) until OD600 of 0.9 was reached. The temperature was 
then lowered to 16 °C and the protein expression was induced with 0.5 mM IPTG 
and grown o/n for 16 h. 
The cells were harvested, re-suspended in lysis buffer (50 mM Tris, 150 mM NaCl, 
20 mM imidazole, pH 7.5) supplemented with 50 µg Dnase from bovine pancreas 
(Sigma), 50 µg lysozyme from chicken egg white (Sigma) and 1 EDTA-free protease 
inhibitor cocktail tablet (Roche), before being sonicated and centrifuged (50,000 g, 
30 min, 277 K on BECKMAN Avanti-J25). The filtered supernatant was applied on a 5 
ml HisTrap HP chelating column, washed with lysis buffer, and the protein was 
eluted with a linear imidazole gradient from 96% buffer A (50 mM Tris, 150 mM 
NaCl, pH 7.5) to 100% buffer B (50 mM Tris, 150 mM NaCl, 500 mM imidazole, pH 
7.5) using an ÄKTA-purifier.  
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Figure 3.3 Chromatogram of TbUGP (construct B) on a HisTrap HP 5 ml column 
The chromatogram describes the UV absorbance on the y-axis in blue in mAU, in 
green a gradient of Buffer B, in brown is the conductivity of the solution, in red 
the collection tubes and the volume in ml on the x-axis . The SDS-page gel on 
the right shows the following from left to right: wash = flow through HisTrap at 
4% of buffer B and 96% buffer A; samples from tubes B7, D5; Lad. = protein 
ladder in kDa (SeeBlue); sample from tube E4. Protein was collected from A6-E5 
for further purification. 
Fractions containing TbUGP were pooled, concentrated and applied on a 
Superdex75 16/60 column, equilibrated with buffer C (50 mM Tris, 150 mM NaCl, 
10% glycerol, pH 7.5). The size-exclusion chromatography fractions containing 
TbUGP were pooled and flash frozen in liquid nitrogen. Aliquots were stored at -
80°C at a concentration of 2 mg/ml.  
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Table 3.3 Amino acid sequence of cleaved TbUGP crystallisation construct B 
LNPPSAFSGAALACLEKMQASGVEEKCIHIFLIQHALVRKGETGYIPEKSISPVESLPFLQGIETKG
ENTALLRQAVVLKLNGGLGTGMGLNGPKSLLQVKNGQTFLDFTALQLEHFRQVRNCNVPFML
MNSFSTSGETKNFLRKYPTLYEVFDSDIELMQNRVPKIRQDNFFPVTYEADPTCEWVPPGHGD
VYTVLYSSGKLDYLLGKGYRYMFISNGDNLGATLDVRLLDYMHEKQLGFLMEVCRRTESDKKG
GHLAYKDVIDETTGQTRRRFVLRESAQCPKEDEDSFQNIAKHCFFNTNNIWINLMELKKMMD
EQLGVLRLPVMRNPKTVNPQDSQSTKVYQLEVAMGAAISLFDRSEAVVVPRERFAPVKTCSDL 
LALRSDAYQVTEDQRLVLCEERNGKPPAIDLDGEHYKMIDGFEKLVKGGVPSLRQCTSLTVRGL
VEFGADVSVRGNVVIKNLKEEPLIIGSGRVLDNEVV 
Table 3.4 Biochemical properties of TbUGP crystallisation construct B 
Number of amino acids: 483 
Molecular weight: 54191.2 
Theoretical pI: 6.03 
Abs 0.1% (=1g/l): 0.588 at 280nm (Artimo, et al., 2012) 
 
The crystallization construct B was provided by the Hui group (Structural Genomics 
Consortium, University of Toronto). The construct was transformed and 
overexpressed in E. coli Bl21(DE3) cells as described previously (Marino, et al., 
2010). In brief, cells were grown o/n at 37 °C in 10 ml of LB media with ampicillin 
(50 µg/ml) and transferred into 50 ml of TB media + ampicillin (50 µg/ml) and 
incubated for 3 h at 37 °C. Subsequently the culture was transferred into 1.8 L of TB 
supplemented with ampicillin and grown till an OD600 of 1 was reached. 
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Overexpression of TbUGP was induced by adding 0.5 mM for an overnight 
incubation at 15 °C. For harvest and protein purification the protocol described 
above (3.1.3) was used and adapted with following changes. The lysis buffer D used 
was 50 mM HEPES pH 7.5, 500 mM NaCl, 5 mM imidazole, and 5% glycerol, and the 
wash buffer E used was 50 mM HEPES pH 7.5, 500 mM NaCl, 30 mM imidazole, and 
5% glycerol. After the HisTrap-column, the protein was treated with TEV protease 
(produced in-house) and dialysed into 10 mM HEPES, 500 mM NaCl, 5 mM 
imidazole and 5 mM DTT o/n. After dialysis, the protein was again applied on a 
HisTrap -column to separate the TEV – tagged and untagged TbUGP (Figure 3.4.).  
 
Figure 3.4 Chromatogram of TbUGP (construct B) on a HisTrap HP 5 ml column 
after TEV – cleavage 
The chromatogram describes the UV absorbance in blue on the y-axis in mAU 
and volume on the x-axis in ml, in green a gradient of buffer B, in brown is the 
conductivity of the solution and in red the collection tubes. The SDS-page gel on 
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the right shows the following from left to right: L = protein ladder in kDa 
(SeeBlue); A10 = flow through HisTrap; D6 = uncleaved TbUGP; ctrl = purified 
TbUGP from previous purification. 
The eluation buffer for Superdex75 16/60 column was 10 mM HEPES, pH 7.5 and 
500 mM NaCl, 5 mM DTT.  
 
Figure 3.5 Chromatogram of TbUGP (construct B) on a Superdex75column after 
TEV – cleavage 
The chromatogram describes the UV absorbance on the y-axis in blue in mAU, 
volume on the x-axis in ml and in red the collection tubes. The SDS-page gel on 
the right shows the following from left to right: L = protein ladder in kDa 
(SeeBlue); samples from the tubes B4, C3, C5, C8 and C9. Protein from C3 to C9 
was collected for further experiments.  
The protein was concentrated up to 17 mg/ml and aliquots were flash frozen in 
liquid nitrogen and subsequently stored at -20°C.  
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3.1.4 Kinetic inhibition assay of TbUGP  
Inhibition of TbUGP was measured using a pyrophosphatase coupled Biomol Green 
assay (Enzo Life Sciences) (Figure 3.6) based on previously published paper (Marino, 
et al., 2010). Biomol Green is a modified malachite-green and therefore very 
sensitive in detecting free phosphate in solution. The change of colour from yellow 
to green was detected at 650 nm in a 96 well plate with a SPECTRA max 340 PC 
spectrometer.  
 
Figure 3.6 Detection of phosphate using BiomolGreen  
Reaction mechanism of TbUGP. The produced pyrophosphate (PPi) is converted 
by pyrophosphatase into free phosphate which is then coloured by 
BiomolGreen and detected in a plate reader at 650 nm. 
The DMSO tolerance for TbUGP in this assay was determined to 5%. The aqueous 
buffer consisted of 50 mM Tris/HCl pH 7.2, 1 mM DTT, 0.1 mM EDTA, 0.1 mM EGTA, 
150 mM NaCl, 10 mM MgCl2 and 0.02% CHAPS. The substrate concentration was at 
Km: 122 µM Glc1P and 53 µM UTP. At a TbUGP concentration of 30 fM the reaction 
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was linear for 30 min. Pyrophosphatase concentration was at 0.1 units per ml. The 
reaction was stopped after 30 min by adding the same volume as the reaction 
volume of Biomol Green. After a colour developing time of 30 min the absorption 
was measured at 650 nm. All compounds were tested with LCMS for purity and in 
the biochemical assay as well in absence of TbUGP to make sure, that inhibitors 
found are not inhibiting pyrophosphatase instead of TbUGP. As a standard inhibitor 
non-hydrolysable Rp-UTP-α-S (BioLog, Germany) was used. 
3.1.5 High throughput screening (HTS) with TbUGP 
The HTS was carried out together with Raffaella Grimaldi. The assay conditions were 
the same as described in 3.1.4., except that different instruments (see below) and 
plates (384 PSF clear well plates) were used. The in-house DDU compound sets 
consisted of a general set (62538 compounds, (Brenk, et al., 2008)), a kinase set 
(6724 compounds, (Brenk, et al., 2008)), the Prestwick Library (1120 compounds) 
and of a fragment library (652 compounds). All HTS libraries were tested at 35 µM 
in the primary screen (single point (SP) and hits from SP in double point 
measurements (DP)) and at 100 µM top concentrations in the potency screen (ten 
point). The fragment set was screened at 500 µM. Compounds were transferred 
from the source plates to the screening plates using the HummingBird instrument 
(DIGILAB). The substrate mix (UTP, Glc1P and pyrophosphatase in buffer) was then 
pipetted into the plates and the reaction was started by adding substrate using an 
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8-channel micro plate dispenser (Thermo Scientific Matrix WellMate). In addition, 
Biomol Green was added and assay plates were read using a PerkinElmer 2102 
Multilabel Reader (Envision), which can read several plates automatically. To 
monitor assay performance, each dispensing and measuring instrument was tested 
before the screen and calibrated if necessary. Two control rows (high/low) were 
measured on each plate together with a standard inhibitor 16 (Table 3.6) or UTP-α-S 
(7, Table 3.5). The high-control was the reaction mixture without compounds and 
the low control was the complete reaction mixture without TbUGP. The signals of 
these wells were averaged (AVHIGH, AVLOW) and used to calculate the signal to noise 
ratio (AVHIGH/AVLOW) and  
G´ = 1 0 3(.KLM8L 	+ 	.KNOP)*LM8L	 0	*NOP  
Equation 3.1 Z-factor (Zhang, et al., 1999) 
(SD: standard deviation; Z´: Z-factor). The ligand efficiency was calculated using the 
following formula: 
  = 0BR/SE		ℎ):	 
Equation 3.2 Ligand efficiency 
(LE = ligand efficiency in kcal/mol per non-hydrogen atom; R = ideal gas constant; T 
= 298K, Ki = binding affinity calculated from IC50 values using  
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Table 3.5 Non-hydrolysable substrate UTP-α-S 
# Structure 
pIC50  for 
WT 
TbUGP 
(G219I–
mutant) 
Hill slope 
7 
 
4.51±0.02; 
(4.86±0.01) 
0.9±0.1 
(0.8±0.1) 
3.1.5.1 Analysis of HTS hits to establish SAR 
In order to be able to establish a SAR, the software ClassPharmer was used with the 
following settings to cluster the screening hits: 
• Cluster by ring system with minimum 1 ring and maximum 3 rings 
• Skip compounds which have more than 20 rings 
• Do not allow portioning of fused rings into individual rings 
• Do not allow connecting of rings using non-ring linker atoms 
• Set in class parameters that the homogeneity level is high, redundancy level 
is low. 
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Compounds spanning a range of potencies in each cluster were selected using 
Pipeline Pilot (Accelrys). Pipeline Pilot is a graphical workflow application, where 
different modules can be used to process, analyse, manipulate and filter tables, 
texts and graphics. In the first step all singletons were rejected. To be able to probe 
one cluster for active compounds, three compounds from each cluster were chosen 
according to the following rules: 
• From each cluster take the compound with the highest PI 
• Take a compound from the same cluster with PI closest to >70% inhibition 
• Take a third compound X (if present) from the same cluster for which PI is 
over 70% -inhibition and less than highest PI.  
3.1.6 NMR fragment screen and analysis 
The NMR fragment screen was carried out as described for Gs6PGDH enzyme 
(2.1.2.1 and 2.1.1) except that for competition 5 mM UTP was added.  
3.1.7 Testing solubility using a nephelometer 
A nephelometer detects insoluble particles in solutions by measuring forward 
scattered light. The particle density in the solution is a function of the reflected light 
hitting the detector. Because the amount of light reflected depends on the shape 
and reflectivity of the particles, a reference sample must be measured to calibrate 
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the nephelometer. Nephelometry was used to determine solubility of compound 
16. As a reference the assay buffer (3.1.4) plus DMSO (2%-5%) was used for 
calibration. Compound 16 was added to the same solution at different 
concentrations (0.1 mM – 3 mM) and measured in triplicates. The reflectivity is 
giving a numeric value. If this value is not more than three times higher as the 
correspondent reference value, the compound was considered to be soluble at the 
given concentration. 
3.1.8 DNA isolation and manipulation 
Plasmid DNA was purified from E. coli (DH5α) using the Miniprep kit from Qiagen. 
The mutation G219I was inserted into the crystallisation construct using site-
directed mutagenesis (Stratagene QuikChange). The following primers (Eurofins 
MWG Operon in Germany) were used plus 10% DMSO in the reaction mix: 
Forward: 5’ CTACATGTTTATATCAAACATAGACAACCTTGGCGCGAC 3’ 
Reverse: 5’ GTCGCGCCAAGGTTGTCTATGTTTGATATAAACATGTAG 3’ 
The DNA was sequenced by the University of Dundee oligonucleotide facility using 
T7 (TAA-TAC-GAC-TCA-CTA-TAG-GG) + T7 terminator (CTA-GTT-ATT-GCT-CAG-CGG-
TG) primers.  
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3.1.9 Crystallisation of TbUGP G219I-mutant and structure 
determination 
Crystals were grown using the hanging drop method in 24-well plates on VDX slides 
(Hampton Research) or with the Phoenix RE (Art Robbins Instruments) using the 
sitting drop method in 96-well MRC 2 crystallisation plates. Several screening sets 
from Hampton Research (PEG/Ion, Index) and from Qiagen (Classics, JCSG+, AmSO4 
Suite) were screened for suitable crystallisation conditions using a robotic system 
Phoenix RE (Art Robbins Instruments). 
 
Hanging drop method 
The G219I-mutant was crystallised in presence of 3 mM UDP-Glc under the same 
conditions as described earlier (Marino, et al., 2010). Crystals were grown using 1 µl 
crystallisation buffer at pH 5.5 (22% PEG 3350 (as precipitant), 0.1 M ammonium 
sulphate, 0.1 M BisTris) from the reservoir and mixed with the same volume of 17 
mg/ml G219I-mutant (in the following buffer: 10 mM HEPES, pH 7.5 and 500 mM 
NaCl and 5 mM DTT) and equilibrated against 500 µl of reservoir. Crystals appeared 
after growing for two days at 20 °C. These were flash-cooled in crystallisation buffer 
with 20% PEG 400.  
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Sitting drop method 
Construct B of TbUGP (Table 3.3) was crystallised with a 100 nl mixture of 3 mM 16 
and 17 mg/ml TbUGP (in the same buffer as G219I-mutant described above) 
together with either 100 nl or 200 nl of the following crystallisation buffer: 0.2 M 
lithium sulphate, 0.1 M Tris/HCl pH 8.5 and 1.26 M ammonium sulphate as 
precipitant. Crystals appeared after growing for two days at 20 °C. These were flash-
cooled in crystallisation buffer with 20% PEG 400 before collection. 
3.1.9.1 Data collection, processing and structure modelling 
X-ray diffraction data for the mutated TbUGP were remotely collected at beamline 
ID14 in the European Synchrotron Radiation Facility (ESRF) in Grenoble (France), 
equipped with a MAR 225 CCD detector. A full data set of 200 images were 
collected from 140 ° - 340 ° with ɸ = 1 and 4 s exposure time. Crystal orientation, 
cell parameters and possible space group were determined using MOSFILM (Leslie 
and Powell 2007; Battye, et al., 2011). Generated reflection lists and integrated 
reflections from the images were scaled and merged using SCALA (Evans 2006; 
2011) from the CCP4 suite of programs (Potterton, et al., 2003). Resolution data less 
than 45 or greater than 2.5 Å were excluded to produce an Rmerge of 0.121. 
Model generation was done using PHASER (McCoy 2007; McCoy, et al., 2007). As a 
model enzyme the coordinates from TbUGP (PDB 3GUE) dimer were used as a 
starting point with a sequence identity set to 0.95 and molecular weight to 56 kD. A 
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solution was found with a rotation function score (RFZ) = 46.0 and a translation 
function score (TFZ) = 36.1. The structure was refined using REFMAC5 (Murshudov, 
et al., 2011) from the CCP4 package. Refinement was done in 20 cycles using a 
manual weighting term of 0.1 at first and automatic weighting for the last 
refinement steps. Iterative model building was carried out using the interactive 
graphics program WinCOOT (v. 0.7.1 -pre) (Emsley and Cowtan 2004; Emsley, et al., 
2010). At first, all amino side chains with no electron density were mutated as 
stubs. The ligand UDP-Glc was added to the structure using the function “Find 
Ligands” and refined using “Real Space Refine Zone” feature. After a refinement 
with REFMAC5 the amino side chains were mutated back and the occupancy of the 
atoms without electron density were set to 0.01. The structure was refined using 
the validation steps available in WinCoot and checked using web-based validation 
server MolProbity (http://molprobity.biochem.duke.edu/) (Chen, et al., 2010) and 
RCSB PDB (http://validate.rcsb.org/). 
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3.2 Results 
3.2.1 Hit discovery by virtual screening  
3.2.1.1 Virtual screening 
The crystal structure of the TbUGP –product complex was determined (Marino, et 
al., 2010).  
 
Figure 3.7 Binding mode of the product UDP-Glc in TbUGP 
Hydrogen-bond interactions between product and TbUGP are indicated as 
dotted lines. Nitrogen atoms are coloured blue, oxygen atoms red, phosphate 
atoms orange, and carbon atoms of the protein white and of the ligand light 
blue. 
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The uracil moiety forms two hydrogen bonds to the enzyme backbone (Gly83 and 
Gly189) and two with the side chain of Gln161 (Figure 3.7). The uridine ring stacks 
with the amide bonds of Gly83, Gly84 and Gly189. The 2-hydroxy group of the 
ribose ring points into a cavity which appears large enough to accommodate a 
mono substituted cyclopentane ring (Figure 3.8a). The phosphate group forms two 
hydrogen bonds with the Lys375 and His190 side chains and the buried glucose 
residue forms hydrogen bonds to Glu279, Glu256 and Asn301.  
To assess if there is a rational basis for selective inhibition of TbUGP over hUGP the 
binding sites of both enzymes were compared. At the time of study no crystal 
structure of hUGP was available. Therefore, a homology model was build (3.1.1). 
Comparison of the homology model and the TbUGP crystal structure revealed that 
all hydrogen-bond interactions that the product forms in TbUGP are conserved in 
the model structure of the complex (Figure 3.9). However, the cavity lying opposite 
of the 2-hydroxy group of the ribose ring of the product in TbUGP is not present in 
the model structure of hUGP (Figure 3.8 b)). This is due to a replacement of Gly219 
in TbUGP with Ile252 in hUGP. 
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Figure 3.8 Surface overlay 
of TbUGP with hUGP-
model (red) with bound 
UDP-Glc 
a) Solvent accessible 
surface of the binding site 
of TbUGP. (b) Alignment 
of TbUPG (coloured 
atoms) and the hUGP-
model (red). For clarity, 
only the solvent 
accessible surface of the 
binding sites and the 
bound UDP-Glc are 
shown. The cavity 
opposite the 2-hydroxy 
group of ribose ring 
(selectivity pocket) is 
blocked in the human model.  
It can be speculated that ligands occupying this cavity would bind selectively to 
TbUGP. From this point onwards, this cavity is called the selectivity pocket.  
Recently, the apo-structure of hUGP was published (Yu and Zheng 2012). 
Comparison of homology model and this structure (PDB code 3R2W) revealed that 
the build hUGP model is structurally very close to the published X-ray structure 
(aligned  Å, Figure 3.9). The side chain location of Ile241 in the hUGP X-ray structure 
blocking access to the selectivity pocket was also predicted correctly (Figure 3.10). 
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Figure 3.9 C-alpha chains overlay of hUGP(red) and hUGP-homology model (white) 
C-alpha chains of h UDP-Glc from TbUGP (yellow carbon atoms) is displayed to 
indicate the location of the active site.  
 
Figure 3.10 Overlay of active sites of hUGP(red) and G219I-mutant(black) 
UDP-Glc from G219I-mutant (in white) is displayed to indicate the location of 
the active site. In pink is Ile241 of hUGP and in green Ile219 of the G219I 
mutant. 
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A hierarchical screening protocol (Figure 3.12) was established to retrieve small 
compounds that bind into the uracil pocket of TbUGP and possibly extend into the 
selectivity pocket. First, a database of commercially available compounds was 
filtered according to physicochemical criteria. Next, a pharmacophore hypothesis 
was derived and used to filter all compounds passing through the first filter. The 
remaining compounds were docked into the TbUGP binding site and promising 
compounds with a favourable, predicted binding mode, were purchased.  
 
Figure 3.11 Surface overlay 
of TbUGP with hUGP 
(green) with bound UDP-
Glc in TbUGP. 
a) Solvent accessible 
surface of the binding site 
of TbUGP.  
b) Alignment of TbUPG 
(coloured atoms) and the 
hUGP-crystal structure 
(green) (PDB 3R2W). For 
clarity, only the solvent 
accessible surface of the 
binding sites and the 
bound UDP-Glc are 
shown. The cavity 
opposite the 2-hydroxy 
group of ribose ring 
(selectivity pocket) is 
blocked in the human 
structure, which is consistent with the human model (Figure 3.8).  
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Figure 3.12 Virtual screening cascade used to identify potential TbUGP inhibitors 
An in-house virtual database of 5.2 million commercially available compounds 
(Brenk, et al., 2008) was filtered according to the following criteria to derive a 
compound set for virtual screening: Only compounds that had less than 24 heavy 
atoms, four or less rotational bonds, two or more hydrogen-bond acceptors and 
one or more hydrogen bond donors, no unwanted (toxic or reactive) groups, were 
allowed to pass this filter. The selection criteria were chosen to obtain fragment-like 
compounds binding into the uracil pocket which were big enough to reach the 
selectivity pocket. In total, 60255 compounds passed this filter. 
The selected subset was further filtered using a protein-based 3D pharmacophore 
to select for compounds that have the required spatial arrangement of functional 
groups to bind into the uracil pocket. The pharmacophore (Fig 3.1) consisted of 
three hydrogen-bond features and an aromatic ring feature to mimic all atoms of 
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the uracil moiety of the product that from hydrogen-bonds with the protein and the 
aromatic ring that stacks with amide bonds (Fig 3.3). With this setup 4916 
compounds fulfilled the pharmacophore requirements. 
In the final step, the compounds passing the previous filter steps were docked into 
the receptor. For all of these compounds a binding mode was generated. Visual 
analysis of the docking poses revealed that many compounds did not occupy the 
uracil binding pocket. As interactions in this pocket were judged to be crucial for 
binding, these compounds were not further considered. In total, 15 of these 
remaining compounds were purchased for binding studies (Table 3.6). Out of those 
four were ring fragments of docked compounds (8, 9, 10, 15) that appeared 
frequently in high-ranking compounds.  
Table 3.6 Compounds shortlisted for binding assays with TbUGP after virtual 
screening  
# Structure 
pIC50 for 
TbUGP 
Hill slope 
8 
 
not active not active 
9 
 
not active not active 
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# Structure 
pIC50 for 
TbUGP 
Hill slope 
10 
 
not active not active 
11 
 
insoluble 
12 
 
not active not active 
13 
 
insoluble 
14 
 
not active not active 
15 
 
not active not active 
16 
 
3.53±0.04 1.1±0.1 
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# Structure 
pIC50 for 
TbUGP 
Hill slope 
17 
 
not active not active 
18 
 
not active not active 
19 
 
not active not active 
20 
 
insoluble 
21 
 
insoluble 
22 
 
≤ 3  
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3.2.1.2 Evaluation of virtual screening hits 
Initial solubility tests indicated that compounds 11, 13, 20 and 21 were not soluble 
at the required concentration for compound evaluation. Therefore these 
compounds were omitted in further studies.  
3.2.1.3 Binding studies using NMR 
NMR provides a relatively cheap, fast and sensitive method to measure weakly 
binding compounds up to mM range (Meyer 1999). With this technique it is also 
possible to identify a binder out of a mixture of several compounds. Therefore, 
compounds were tested for binding to TbUGP using two NMR experiments. First, 
1H-NMR spectra for all compounds were recorded. Subsequently, cocktails 
containing a mixture of 10 different compounds with the protein were prepared 
and STD (Figure 3.13, Figure 3.15) and wLOGSY (Figure 3.14, Figure 3.16) spectra 
were measured. The compounds which gave a positive signal in the STD and 
wLOGSY experiments were tested for interactions. The substrate UTP was added to 
the mixture to displace bound compounds in the active site and the spectral 
measurements were repeated. Only two compounds (16, 22) showed binding to 
TbUGP as in both experiments (STD + wLOGSY, Figure 3.14 and Figure 3.15). A signal 
reduction after adding the substrate UTP was only observed for compound 16 
(Figure 3.14.) indicating that this compound was accommodated in the UTP binding 
site.  
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Figure 3.13 NMR STD - spectra for 16 showing signal reduction after adding UTP 
In green is the reference spectrum of compound 16, in blue the STD – spectrum 
of the compound and in red the STD – spectrum when substrate UTP is added. 
 
Figure 3.14 NMR wLOGSY - spectra for 16 showing signal reduction after adding 
UTP 
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A wLOGSY spectrum from TbUGP with inhibitor 16 added. In blue is the wLOGSY 
spectrum without the substrate UTP and in red the reduced signal when UTP is 
added. 
 
Figure 3.15 TbUGP - STD spectra of compound 22 in a mixture  
In green is the reference spectrum of compound 22, in blue the STD – spectrum 
of the compound mixture and in red the STD – spectrum when substrate UTP is 
added. 
 
Figure 3.16 TbUGP - wLOGSY spectra of compound 22 in a mixture 
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In green is the reference spectrum of compound 22, in blue the wLOGSY – 
spectrum of the compound mixture and in red the wLOGSY – spectrum when 
substrate UTP is added. 
3.2.1.4 Inhibition assay with virtual screening hits 
All compounds (Table 3.6) were tested in two independent measurements. For each 
measurement one replication was carried out and was performed under the same 
conditions as previously described (3.1.5) at concentrations up to 1 mM (as 
described in 3.1.5). The only inhibitors found were 16 and 22, with 16 showing 76% 
inhibition at 1 mM and 22 showing 50%. Only for compound 16 a dose-response 
curve could be recorded. To ensure that the compound was dissolved at high 
concentrations, the solubility was determined using a nephelometer. The data 
showed that compound 16 was not entirely soluble at 2 mM when the assay buffer 
contained 1 % DMSO. However, when the DMSO concentration was increased to 5 
% compound 16 was completely dissolved. Therefore, a DMSO concentration of 5 % 
was used in the following assays. Under these conditions, the inhibitor has a pIC50 of 
3.53±0.04 and a Hill slope of 1.1±0.1 (Figure 3.17).  
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Figure 3.17 Dose response curve of compound 16 
Dose-response curve with error bars for each data point from two experiments 
(each with n=4), percentage inhibition on y-axis and compound concentration in 
µM on x-axis (logarithmic scale). Points were fitted using a two parameter 
equation (Equation 2.3). Analysis from two experiments returns a pIC50 = 
3.53±0.04 and a Hill slope of 1.1±0.1 (mean ± SD; N=2). 
3.2.1.4.1 Determination of mode of inhibition of compound 
16 
Inhibition of 16 was measured at different substrate (UTP) concentrations to 
determine the mode of inhibition of this compound. Following the Cheng-Prusoff 
equation 
TUVW = XY Z[ + [\][X]]^ 
Equation 3.3 Cheng – Prusoff equation 
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(Cheng and Prusoff 1973) the IC50 for a competitive inhibitor rises with increasing 
concentration of the competing substrate is increased. With a substrate 
concentration at Km the IC50 = 2Km. When substrate concentration is increased to 5 
times Km IC50 will increase 3 times (from 303 µM to 909 µM; IC50 = 6Km) and an 
increase of the substrate concentration to 10 times Km will increase IC50 5.5 times 
(from 303 µM to 1667 µM; IC50 = 11Km). 
Therefore, in the inhibition assay the UTP concentration was increased to 5 times 
and 10 times the Km value of UTP (53 µM) to determine if the IC50 values changed as 
expected for a competitive inhibitor. Under these conditions, 29% and 11% enzyme 
inhibition at 2 mM of 16 were observed respectively (Figure 3.18). Due to solubility 
limits of 16 a full dose- response curve could not be measured and no IC50 values at 
higher substrate concentration could be determined. Nevertheless, a clear loss of 
activity could be observed as expected for a competitive inhibitor.  
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Figure 3.18 Shift in pIC50 for 16 at a substrate concentration of 5 times and 10 
times the Km 
Dose response curve of 16 (black dots) was taken from (Figure 3.17). Red dots 
were determined at 5 times Km (265 µM) and green squares at 10 times the Km 
(530 µM). Percentage inhibition on y-axis is plotted versus compound 
concentration in µM on x-axis (logarithmic scale). Points were fitted using a two 
parameter equation (Equation 2.3). (mean ± SD; N=2). 
3.2.1.4.2 Evaluation of binding mode of compound 16 
An attempt was made to determine the binding mode of 16 in TbUGP using X-ray 
crystallography. The strategy was either to obtain apo crystals of TbUGP to be able 
to soak compound 16 or to co-crystallise TbUGP with 16. The best co-crystallised 
crystals grew in the JCSG+ set (position E4) from Qiagen (for crystallisation 
condition see 3.1.9). Although the crystals were very small (< 20 µM), an attempt 
was made to collect reflection data at ESRF facility in France. Unfortunately the 
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collected x-ray data was of bad quality so it was not possible to determine the 
structure. Attempts to grow larger crystals were unsuccessful.  
In the proposed binding mode, part of the ligand is occupying the selectivity pocket 
which is not present in hUGP (Figure 3.8 and Figure 3.19a). For this reason a point 
mutation was introduced in TbUGP where Gly219 was changed to Ile that is present 
in hUGP at this place and restricts access to the selectivity pocket (Figure 3.19b). We 
hypothesised, that compound 16 should not fit in the cavity any longer and 
therefore not bind to the mutated enzyme if the proposed binding mode is correct 
(Figure 3.19b). 
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Figure 3.19 Comparison of docked compound 16 in wild type (a) and mutated (b) 
TbUGP structure 
a) Structure of wild type TbUGP with bound product UDP-Glc in blue and 
proposed binding mode of 16 in pink. The coupled ring system is pointing into 
the selectivity cavity. b) Structure of the G213I-mutant, where the selectivity 
cavity is partly closed resulting in a clash with compound 16 in the docked 
binding mode of the wild type enzyme. 
The protein containing the point mutation was purified like the wild type and 
crystallized under similar conditions (Table 6.2). 
In the F0-Fc electron density map the position of the isoleucine side chain was 
clearly defined (Figure 3.20). Superposition of G213I from TbUPG and hUGP show 
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that I213 adopts a different conformation (Figure 3.10). As a consequence the 
selectivity pocket is still partially accessible but not large enough to accommodate 
16 in the same binding mode as suggested for the wild type enzyme without a clash 
(Figure 3.19b).  
 
Figure 3.20 Binding site of G219I–mutant with FO-FC electron density  
The FO-FC electron density map shown as green mash (at 1.5 sigma) was 
calculated without the side chain of Ile219 and UDP-Glc present in the 
structure.  
The mutated enzyme was kinetically characterized. The enzyme was still active but 
compared to the wild type, the Km of UTP changed from 53 µM to 18 µM and of Glc-
1P from 122 µM to 20 µM (Table 3.7).  
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Table 3.7 Comparison of Km values of wild type and G219I-mutant of TbUGP 
TbUGP G219I-mutant 
UTP Km [µM] Glc-1P Km [µM] UTP Km [µM] Glc-1P Km [µM] 
53 122 18 20 
 
Compound 16 showed no activity for G219I-mutant to a concentration up to 1 mM 
but G219I-mutant was still inhibited by the substrate-like inhibitor UTP-α-S (7) 
(Figure 3.21). 
 
Figure 3.21 Dose-response curve for substrate like inhibitor UTP-α-S 
Dose-response curve with error bars for each data point from two experiments 
(each with n=2), percentage inhibition on y-axis and compound concentration in 
µM on x-axis (logarithmic scale). Points were fitted using a two parameter 
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equation (Equation 2.3). Analysis from two experiments returns a pIC50 = 
4.86±0.01 and a Hill slope of 0.8±0.1 (mean ± SD; N=2). 
3.2.1.5 Inhibition of hUGP by compound 16 
The inhibition constant of 16 with hUGP was determined (Figure 3.22). The 
compound has a pIC50 value of 5.3 and a Hill slope of 4.2. 
 
Figure 3.22 Dose response curve of 16 with hUGP (measured by Raffaella 
Grimaldi) 
Dose-response curve from one experiment (with n=2), percentage inhibition on 
y-axis and compound concentration in µM on x-axis (logarithmic scale). Analysis 
from the experiment returns a pIC50 = 5.3 and a Hill slope of 4.2.  
Unfortunately, the available amount of hUGP was not sufficient to produce any 
more data with this enzyme. 
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3.2.1.6 SAR around compound 16 
To establish SAR around compound 16, the Pipeline pilot standard module 
“Substructure Filter from File” was used to retrieve analogues of compound 16. This 
module performed a substructure search in the in-house database (Brenk, et al., 
2008). From the few substructures that came through the filter, only 4 were 
available for purchase (Table 3.8). The four analogues were tested using NMR and 
biochemical assay.  
In the NMR Screen all analogues except 26 gave a signal in the STD and wLOGSY 
experiments. The signals were reduced when UTP was added suggesting, that they 
are binding in the substrate binding site.  
Unfortunately none of the compounds showed activity up to 1 mM in the 
BiomolGreen coupled assay.  
Table 3.8 Purchased analogues of compound 16 
# Structure 
23 
 
24 
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# Structure 
25 
 
26 
 
 
3.2.2 Hit discovery using HTS  
The in-house DDU libraries (3.1.5) were screened using BiomolGreen coupled 
enzyme assay. The best performance was achieved at 30 pM TbUGP and substrate 
concentration at Km with a signal to noise ratio = 2.00 and Z´= 0.84 in average.  
The HTS primary screen came back with over 2000 hits from the double point – 
measurements. To see if the hits displayed SAR a maximum substructure analysis 
was carried out using ClassPharmer™ (Simulations Plus, Inc.). Next, using Pipeline 
Pilot (Accelrys), three compounds from each generated class were select to cover a 
range of PI values. This filtering step reduced the amount of compounds to 377. 
These were analysed by kinetic -potency screens (done by Raffaella Grimaldi) and 
tested using surface plasmon resonance (SPR) (done by Iva Hopkins Navratilova). 
The best binders from both screens were compared. The analysis showed that the 
best hits from the potency screen were generally not confirmed using SPR. Further 
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the best binders in SPR, except one, had Hill slopes either < 0.5 or > 1.6. Only two 
compounds (27 and 28) were found to be potent in both screens. These compounds 
do not share the same scaffold or pharmacophore, so no SAR could be developed 
from it.  
Table 3.9 Best binders in SPR and potency screen from filtered HTS 
# Structure 
pIC50  
for 
TbUGP 
Hill 
slope 
27 
 
4.74 1.4 
28 
 
5.74 1.1 
 
3.2.3 Screening of fragment library 
The fragment library was screened by NMR and by using the kinetic assay. The hit 
rate of the NMR assay was very high (>40% of screened compounds gave a positive 
signal in either STD or wLOGSY experiment). However, for most compounds no 
signal reduction was observed after adding UTP, indicating that the screening setup 
103 
 
 
 
is valid. When screening the fragment library with the kinetic assay, a signal to noise 
ratio = 2.1 and Z´=0.82 was obtained. As a result 49 compounds with PI ≥ 75% were 
selected for potency screen (Table 3.10). 
 
 
 
Figure 3.23 PI of fragment set 
Distribution of average PI of the fragment set with PI on the x – axis and 
number of compounds on the y- axis. 
The table shows all 49 compounds with the corresponded pIC50 ranges, the number 
of compounds, the number of compounds which inhibited pyrophosphatase and 
the amount of these compounds which were confirmed as binder in the NMR 
experiments. Some of the interfering compounds were found to bind to TbUGP in 
the NMR experiment, which is shown in the red brackets (Table 3.10.)  
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Table 3.10 Fragment screen result summary 
pIC50  # TbUGP # Interfering 
with PPase 
# TbUGP NMR 
positives 
< 5 6 2 3 (1 of 
interfering) 
5 – 4.7 6 1 4 
4-7 – 4.5 4 2 1 (1 of 
interfering) 
4.5 - 4.4 2 - 2 
4.4 - 4.3 3 2 1 (1 of 
interfering) 
4.2 - 4 7 2 3 
4 – 3.7 13 6 4 (2 of 
interfering) 
3.7 – 3.5 5 - 2 
3.5 – 3.4 1 1 1 (1 of 
interfering) 
>3.3 2 - - 
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3.3 Discussions of the UGP – project 
By using a virtual screening approach, 15 compounds were shortlisted for 
biochemical testing with TbUGP (Table 3.6) out of which one inhibitor (16) was 
identified. This is a very high hit rate, especially considering that only 15 out of 5.2 
million commercially available compounds were tested. Virtual screening was again 
proven to be an efficient method to find inhibitors in the early drug development 
stage for a target for which no drug-like inhibitors were known at the onset of the 
study.  
The mode of binding of the virtual screening hit 16 was determined using NMR 
experiments and enzyme kinetics. NMR experiments showed that 16 binds to 
TbUGP and competes with UTP for the same binding site (3.1.6, 3.2.3). However, by 
adding 5 mM UTP the signal in the saturation transfer difference (STD) experiment 
was not fully reduced (Figure 3.13) and in the wLOGSY experiment not inverted 
(Figure 3.14). This is probably due to the fact that UTP binds only relatively weakly 
to TbUGP (Km: 53 µM, 3.1.4). It is likely, that the competition of the compound 
would have been much more clearly observed in the spectra if a potent inhibitor for 
TbUGP was available. In addition to the NMR experiments, studies of the binding 
kinetics were carried out to determine the mode of inhibition of 16. By increasing 
the concentration of UTP, the inhibition of TbUGP decreased, indicating that the 
inhibitor binds competitively into the substrate binding site (Figure 3.17, Figure 
3.18). 
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To further probe the binding mode of 16, a point mutation was introduced into 
TbUGP to close the selectivity pocket as found in the structure of the human 
homolog (Figure 3.8). In the suggested binding mode (Figure 3.19a) the ligand is 
occupying this pocket. Hence, it was expected that the compound would no longer 
inhibit the mutated enzyme. Introducing the mutation proved challenging, because 
the required primers were prone to intramolecular interactions and formation of 
secondary structures (Figure 3.24). The site-directed mutagenesis was only 
successful after adding 10 % DMSO to disturb these unwanted interactions. Analysis 
of the crystal structure of the mutated enzyme (Figure 3.19b) revealed that the 
selectivity pocket was not entirely closed as expected based on the structure of 
hUGP but far enough to restrict binding of 16 in the model binding mode of the 
compound in the wild type enzyme (Figure 3.19a). Compound 16 showed no 
inhibition with mutated TbUGP up to a concentration of 1 mM which is consistent 
with the suggested binding mode.  
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Figure 3.24 Secondary structures of used primers.  
Images produced by the sir graph utility of the mfold program (Zuker 2003) 
Analogues (Table 3.8) of 16 were purchased and tested for activity to establish SAR. 
All analogues possess the pyrazole group which is presumably binding into the 
uracil binding site (Figure 3.19a). They also contain a moiety which can extend into 
the selectivity cavity. However, none of the compounds have a hydrogen-bond 
acceptor functionality which corresponds to the nitrogen atom of the bicyclic ring 
system of 16, which forms a hydrogen-bond with Gly84. (Note, that compound 23 is 
similar to 16 but has got an oxygen atom instead of the nitrogen in the bicyclic ring 
system, however, due to its environment in the ligand it is at best a very poor 
hydrogen-bond acceptor). Therefore the analogues were expected to be less potent 
than 16. All analogues except 26 showed competitive binding in the NMR 
experiments at 1 mM. It is likely that the nitrogen atom of the pyrazole ring in 26 
has no hydrogen-bonding partner in the protein leading to reduced affinity. 
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Although binding was measured by NMR for the remaining compounds, binding was 
too weak to be detected in the biochemical assay up to 1 mM. This might indicate 
that the interaction of the nitrogen atom of the thiazole moiety in 16 with Gly84 is 
crucial for affinity. To develop further SAR and to improve potency, more analogues 
must be designed and synthesized. 
The virtual screening hit 16 was also tested for inhibition with hUGP using the 
BiomolGreen kinetic assay. Despite the assumption that 16 should not inhibit hUGP 
as the selectivity pocket is closed in the crystal structure (Figure 3.11), a pIC50 of 5.3 
was measured with a Hill slope of 4.2. This Hill slope is too steep for a competitive 
inhibition and binding does therefore not follow the law of mass action for a single 
binding site. A Hill slope > 1 can indicate either non equilibrium state, allosteric 
binding or positive cooperation (Heck 1971). That would mean that the binding of 
16 into one active site of the enzyme increases its affinity for the other sites. These 
modes of inhibition are different from the one in TbUGP. It is therefore not clear 
where and how compound 16 is binding to hUGP. The amount of hUGP enzyme 
available was not sufficient enough to accomplish further necessary experiments. 
Inhibitor 16 has a molecular weight of 201 Daltons and a ligand efficiency of 0.4 
kcal/mol per non-hydrogen atom and an alogP of 2.7. This makes it a good starting 
point for further optimization (Hopkins, et al., 2004). It is possible, that some 
changes in the fused ring system will not only improve the potency of the 
compound but also make it more selective for TbUGP as the requirements for 
binding to the alternatives sites in hUGP might be different. With modifications on 
109 
 
 
 
16 it will be possible to learn more about the inhibition mode in hUGP and develop 
highly potent and selective inhibitors.  
 
HTS of over 70 000 compounds produced thousands of hits but no obvious SAR. 
Many hits had Hill slopes that were not consistent with competitive inhibition. Even 
after clustering the hits in classes and testing them using SPR, the hits could not be 
confirmed. For this reason an alternative inhibition assay was used. This was carried 
out by Sabine Kuettel using a Dionex HPLC instrument that directly measured the 
production of the product UDP-Glc (data not shown). She selected the top hits from 
the HTS, SPR and fragment screening and tested them by using 7 as a control (Table 
3.5). She could not confirm that any of the compounds (including 16) were active. 
The reason for the unexpected behaviour of TbUGP under different assay conditions 
is currently unclear.  
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4 Summary and Conclusions  
In this study the process from assay development to hit validation for two different 
targets for HAT, Tb6PGDH and TbUGP, was carried out. For hit identification 
different modern techniques were used like in silico virtual screening or 
experimental screening using SPR, NMR and HTS.  
4.1 Summary and conclusions regarding 6PGDH – Project  
The aim of this project was to use a thermophilic model system like Gs6PGDH 
instead of the highly instable Tb6PGDH and search for binders using a fragment 
screening by NMR (2.1.2). Because the substrate (6PG) pocket of both enzymes is 
conserved (Figure 2.8) it was a reasonable assumption that compounds found to 
bind to the model enzyme should also bind in the same way to the target enzyme. 
The selectivity over h6PGDH could then be achieved by chemically expanding the 
compounds into the co-factor NADP+ - binding site. Structural analysis suggests that 
the differences around the co-factor should be sufficient to achieve that goal 
(Figure 2.10). For the kinetic studies a colorimetric assay was developed measuring 
the production of NADPH at 340 nm (2.1.3.1). This assay is easy to perform but has 
several limitations. Compounds that absorb at 340 nm or interact with NADPH 
cannot be measured and are excluded from further studies.  
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To validate Gs6PGDH as a good model it was planned to test compounds which 
were found to inhibit TbUGP (Ruda, et al., 2010). This first revealed a discrepancy 
between the published data and the ones collected for the model enzyme (2.2.2). 
However, this data does not disproved Gs6PGDH as a good model enzyme, because 
the published data lacks of many important details and is therefore uncertain 
(2.3.1). The fragment screen resulted in many hits from which only two acids were 
found to weakly bind to Gs6PGDH using calorimetric assay (2.2.5). It seems that 
most of the NMR - hits were not potent enough to be detected by a biochemical 
assay. 
In Summary this study was unfortunately not able to successfully determining a 
binding mode of published virtual screening hits of Tb6PGDH and has not 
discovered any new potent, fragment-like inhibitors. The polar binding pocket and 
the instability of the enzyme suggesting that Tb6PGDH is not a suitable target for a 
structure-based hit discovery approach.  
4.2 Summary and conclusions regarding UGP – Project  
For the target TbUGP a very first, drug-like inhibitor (16) was discovered using in 
silico virtual screening. From an in-house virtual library of 5.2 million commercial 
available compounds, fifteen were purchased for activity test from which two 
showed activities in the kinetic assay but only for 16 a dose response curve could be 
measured. Compound 16 has a molecular weight of 201 Dalton, a ligand efficiency 
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of 0.4 kcal/mol per non-hydrogen atom, an alogP of 2.7 and inhibits TbUGP with a 
pIC50 of 3.53±0.04 and a Hill slope of 1.1±0.1. NMR and enzyme inhibition data for 
the compound is consistent with it being a competitive inhibitor (3.2.1.3 and 
3.2.1.4). This is the first, not substrate like competitive inhibitor found for TbUGP. 
The proposed binding mode of 16 was evaluated using mutation studies (3.2.1.6) 
and crystallography (3.1.9). Compound 16 was expected to bind into the UTP pocket 
and expand into a cavity present in TbUGP (Figure 3.19). A G219I - mutation of 
TbUGP results in a blocked cavity, similar as found in hUGP (Figure 3.10). As 
expected 16 was no longer inhibiting the G219I–mutant up to 1 mM but was still 
inhibiting hUGP. The proposed selectivity of 16 could not be confirmed in this study. 
To establish a SAR around compound 16 a substructure search was carried out from 
which four analogues were purchased (Table 3.8). The NMR – screen showed that 
three of four compounds bind competitively to TbUGP. A biochemical test showed 
that none of these compounds were active up to 1 mM. That means that the 
biochemical assay is not sensitive enough to detect such weak binders.  
A HTS with the DDU in-house fragment library using a biochemical BiomolGreen 
coupled enzyme assay, SPR and NMR came back with a high unusually hit – rate. 
The best compounds from each test did not coincide with each other. To be able to 
explain that behaviour the BiomolGreen assay was replaced by an assay using a 
Dionex HPLC instrument that directly measured the production of the product UDP-
Glc. This replacement did not clarify the results but raised even more questions, as 
none of the hits (including 16) could be confirmed in this assay. Therefore a new 
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strategy should be developed to tie up all the results collected and to explain that 
strange behaviour observed in this study.  
In summary, based on the NMR data and the data collected using the BiomolGreen 
assay with the wild type and G219I–mutant, compound 16 provides a good lead for 
further development of TbUGP inhibitors. Derivatives of 16 could result in a more 
potent and selective inhibitor and become a good lead compound for further 
development.  
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5 Outlook 
6PGDH has proven to be a difficult target. The fact, that no binding modes inhibitors 
are know which were not substrate like and that the binding pocket of 6PGH 
enzyme is challenging to address, together with the instability of Tb6PGDH, makes 
this target not a good candidate for further studies. There are better targets for HAT 
to concentrate on.  
One example is UGP. This thesis showed that this enzyme is accessible to a rational 
hit discovery approach. The crystal structures of TbUGP and h which makes it 
available for structure – based design.  
Further studies should be carried out to explain what the mode of action of 16 with 
hUGP is. A crystal structure of hUGP with 16 could help to understand the 
biochemical data and provide guidance for the synthesis of selective derivatives of 
16. A derivative with a higher binding affinity for TbUGP would prove beyond doubt 
that 16 is not a false positive.  
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6 Appendix 
6.1 Recipe for auto-induction media 
Table 6.1 Autoinduction media 
For 1 L autoinduction media 
5g Yeast extract 
 
20ml 50x5052 
50x5052: 
250g glycerol 
25g glucose 
10g α-lactose 
1ml 1M MgSO4 
10g Tryptone  
50ml 20xNPS 
20xNPS: 
66g (NH4)2SO4 
136g KH2PO4 
142g Na2HPO4 
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6.2 Crystallographic statistic tables 
Table 6.2 Crystallographic data and refinement statistics of G219-mutatant ligand 
complex.  
Details of Data Collection 
Space group C 2 
Unit cell dimensions: a, b, c (Å) 166.2, 78.4, 112.3 
α=γ=90 °, β=118 ° 
Resolution range (Å) 45 -2.5  
No. reflections 155335 
No. unique reflections 41173 
Redundancya 3.8 (3.5) 
Completenessa (%) 93.4 (92.8) 
Wilson B (Å2) 18.2 
<I/σ(I)> 8.8 (2.9) 
Rmerge
b (%) 12.1 (42.8) 
Refinement Statistics 
Rwork
c
 / Rfree
d (%) 22.9 / 29.6 
Number of: 
Protein residues 
Chain A 
Chain B 
 
 
466 
459 
117 
 
 
 
Water molecules 
UPG (Chain A + B) 
118 
2 
Average B-factors (Å2) 
Overall / side chain / main chain 
UPG (chain A / B) 
 
20.7 / 21 / 20.3 
10.3 / 7.8 
r.m.s.d. from ideal values: 
Bond lengths (Å) 
Bond angles (˚) 
 
0.009 
1.360 
Ramachandran plot analysis (%) 
Favourable e 
Outliers e 
 
876 (95.8) 
2 (0.2) 
  
a Values in parentheses refer to the highest resolution shell (2.64-2.5 Å). 
 b B+_` = ∑ℎ∑  ||(ℎ, )0	< I(ℎ) > ∑ℎ∑  I(ℎ, ); where I(ℎ, ) is the intensity 
of the th measurement of reflection ℎ and <	I(ℎ)> is the mean value of I(ℎ, ) 
for all  measurements. c. B	_g = ∑ℎD ||h| 0 |h||/∑ |h|, where h is the 
observed structure-factor amplitude and the h  is the structure-factor amplitude 
calculated from the model. d. Bj_ is the same as B	_g except calculated with a 
subset, 5 %, of data that are excluded from refinement calculations. e. According 
to MolProbity (http://molprobity.biochem.duke.edu) 
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Table 6.3 Crystallographic data and refinement statistics of Gs6PGDH.  
Details of Data Collection 
Space group P212121 
Unit cell dimensions: a, b, c (Å) 67.8, 119.8, 141.9 
Resolution range (Å) 38.8 -2.7  
No. reflections 144947 
No. unique reflections 31971 
Redundancya 4.5 (4.0) 
Completenessa (%) 98.6 (97.0) 
Wilson B (Å2) 18.2 
<I/σ(I)> 11.2 (2.5) 
Rmerge
b (%) 13.1 (57.6) 
Refinement Statistics 
Rwork
c
 / Rfree
d (%) 21.2 / 27.9 
Number of: 
Protein residues 
Chain A 
Chain B 
Water molecules 
 
 
464 
466 
26 
Average B-factors (Å2) 
Overall / side chain / main chain 
 
26.7 / 27.5 / 25.9 
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r.m.s.d. from ideal values: 
Bond lengths (Å) 
Bond angles (˚) 
 
0.01 
1.347 
Ramachandran plot analysis (%) 
Favourable e 
Outliers e 
 
889 (96.3) 
3 (0.3) 
  
a Values in parentheses refer to the highest resolution shell (2.64-2.5 Å). 
 b B+_` = ∑ℎ∑  ||(ℎ, )0	< I(ℎ) > ∑ℎ∑  I(ℎ, ); where I(ℎ, ) is the intensity 
of the th measurement of reflection ℎ and <	I(ℎ)> is the mean value of I(ℎ, ) 
for all  measurements. c. B	_g = ∑ℎD ||h| 0 |h||/∑ |h|, where h is the 
observed structure-factor amplitude and the h  is the structure-factor 
amplitude calculated from the model. d. Bj_ is the same as B	_g except 
calculated with a subset, 5 %, of data that are excluded from refinement 
calculations. e. According to MolProbity (http://molprobity.biochem.duke.edu) 
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6.3 List of Abbreviations 
• °C – degree Celsius 
• µ – mycro  
• 6PGDH – 6-Phosphogluconate dehydrogenase 
• CHAPS – 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
• DMSO – dimethyl sulfoxide 
• DNA – deoxyribonucleic acid 
• Dnase – desoxyribonuklease 
• DTT – dithiothreitol 
• EDTA – ethylenediamine tetraacetic acid 
• EGTA – ethylene glycol tetraacetic acid 
• ESRF – European synchrotron radiation facility 
• G – earth´s gravitational acceleration 
• g – Gramm 
• Gs – Geobacillus stearothermophilus 
• h – hour/s 
• h - human 
• HEPES – 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
• HPLC – high performance liquid chromatography 
• IPTG – Isopropyl-β-D-thiogalactopyranosid 
• K – Kelvin 
• kDa - kilodalton 
• kg – Kilogramm 
• l – litre 
• m – milli 
• M – Molar 
• NADP+ –  nicotinamide adenine dinucleotide phosphate (reduced form 
NADPH) 
• nm – nanometre 
• o/n – over night 
• OD600 optical density at 600nm 
• ORF – open reading frame 
• PCR – Polymerase chain reaction 
• PDB – protein databank 
• PEG – polyethylene glycol 
• PPase -pyrophosphatase 
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• QSAR – quantitavie structure-activity relationship 
• RMS – root mean square 
• RMSD – root mean square deviation 
• Rpm – rounds per minute 
• TB – Terrific Broth (media) 
• Tb – Trypanosoma brucei 
• TEV – Tobacco Etch Virus 
• Tris – 2-amino-hydroxymethyl-propane-1,3-diol  
• U – Uracil 
• UDP – Uridine diphosphate 
• UGP – UDP-glucose pyrophosphorylase 
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